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Metabolismen i hjernen til mus behandlet med acetyl-l-carnitine og to 
musemodeller for temporallappsepilepsi 
 
Sykdommer i hjernen, som epilepsi og depresjon, er vanlige. Ikke bare påvirker disse 
sykdommene livene til den enkelte pasient og de pårørende, men de utgjør også store 
utfordringer for samfunnet. Felles for de fleste hjernesykdommene er at vi i liten grad 
kjenner til de underliggende mekanismene som ligger bak dem. Derfor er det også 
vanskelig å utvikle ny og effektiv behandling. Vi trenger med andre ord mer 
forskning for å forstå bedre hvordan hjernen fungerer og hvordan sykdommene arter 
seg. 
I min doktorgrad har jeg arbeidet med to musemodeller med epilepsi og et 
næringsstoff, acetyl-l-carnitine. Målet med avhandlingen har vært å undersøke 
endringer i stoffskiftet i hjernen til mus med epilepsi og hvordan acetyl-l-carnitine 
påvirker stoffskiftet i hjernen både til friske mus og mus med epilepsi. Ved hjelp av 
blant annet avansert magnetisk resonans (MR) teknologi har jeg målt nivåene av ulike 
stoffer i hjernen til mus. 
Resultatene av arbeidet mitt viser at de epileptiske musene hadde reduserte 
nivåer av det vanligste signalstoffet i hjernen, glutamat, i området 
hippokampusformasjonen. Videre tyder flere funn på at funksjonen til mitokondriene 
i den epileptiske hjernen er redusert. Acetyl-l-carnitine forebygget ikke kramper hos 
epileptiske mus, men motvirket visse spesifikke endringer i stoffskiftet i hjernen til 
disse musene. I friske mus økte acetyl-l-carnitine energilagrene i hjernen samt 
nivåene av to viktige signalstoffer i hjernen, noradrenalin og serotonin, som begge 
spiller sentrale roller i behandlingen av depresjon.  
Min forskning har gitt mer innsikt i endringer i hjernen ved epilepsi som kan 
gi grunnlag for bedre diagnostikk og behandling av sykdommen. I tillegg gir 
resultatene grunnlag for videre utprøving av acetyl-l-carnitine i behandlingen av ulike 
hjernesykdommer. 
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He remembered that during his epileptic fits, or rather immediately preceding them, 
he had always experienced a moment or two when his whole heart, and mind, and 
body seemed to wake up to vigor and light; when he became filled with joy and hope, 
and all his anxieties seemed to be swept away for ever; these moments were but 
presentiments, as it were, of the one final second (it was never more than a second) in 
which the fit came upon him. That second, of course, was inexpressible…  That there 
was, indeed, beauty and harmony in those abnormal moments, that they really 
contained the highest synthesis of life, he could not doubt, nor even admit the 
possibility of doubt… These instants were characterized—to define it in a word—by 
an intense quickening of the sense of personality. Since, in the last conscious moment 
preceding the attack, he could say to himself, with full understanding of his words: “I 
would give my whole life for this one instant”… 
 
Excerpt from the novel “The Idiot” by Fyodor Mikhailovich Dostoyevsky, 
written in 1869, in which the experience of an epileptic seizure is described.
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Sammendrag 
 
Epilepsi er en av de vanligste nevrologiske sykdommene i verden og 
temporallappsepilepsi (TLE) er sannsynligvis den hyppigste formen for epilepsi. 
Behandlingen av TLE er i dag ikke god nok og opp til 60% av personer med TLE blir 
resistente mot gjeldende epilepsimedisiner. Selv om tilstanden ofte kan kureres med 
kirurgi, har sosiale og psykiske ringvirkninger av tilstanden gjerne manifestert seg 
lenge før kirurgi gjennomføres. Mekanismene bak TLE er ennå ikke klarlagte, men 
mye tyder på at forstyrret metabolisme, særlig i hjernestrukturen hippocampus, bidrar 
til patogenesen. Ved å belyse disse metabolske endringene kan vi oppdage nye mål 
for behandling av TLE samt forbedre diagnostikken. I Artikkel 2 og 3 undersøkte vi 
metabolismen i hjernen til to modeller for TLE i mus, henholdsvis pentylenetetrazole 
(PTZ) kindling modellen og pilocarpine status epilepticus modellen. I tillegg 
evaluerte vi de antiepileptiske virkningene til acetyl-l-carnitine (ALCAR) på anfall og 
metabolisme i PTZ kindling modellen. 
ALCAR er et kosttilskudd som er tilgjengelig i helsekostbutikker i utlandet men 
ikke i Norge. ALCAR finnes naturlig i kroppen og er involvert i frakten av acetyl-
enheter over den mitokondrielle membranen. I mer enn tjue år har ALCAR blitt prøvd 
ut som terapeutisk virkemiddel ved ulike sykdommer i hjernen. Blant annet har 
behandling med ALCAR til pasienter med depressive tilstander gitt gode resultater. 
Administrering av én enkelt dose ALCAR til rotter gir økt energitilgjengelighet i 
hjernen og beskyttelse mot nevrotoksiske insulter som iskemi og oksidativt stress. Det 
har derimot vært en mangel på studier som viser langtidsvirkningene av ALCAR 
behandling på metabolismen i hjernen. I Artikkel 1 undersøkte vi virkningen av 
ALCAR gitt til mus i 25 dager på energi og nevrotransmitter homeostasen i hjernen. 
I alle de tre studiene i denne avhandlingen skaffet vi detaljert oversikt over 
metabolske endringer i hjernebarken og hippokampusformasjonen (HF) til mus ved 
hjelp av 1H nukleær magnetisk resonans (NMR) spektroskopi og væskekromatografi. 
For å studere metabolismen av glukose injiserte vi mus med 13C merket glukose og 
undersøkte hjerneekstrakt med 1H og 13C NMR spektroskopi samt gass kromatografi-
masse spektrometri. 
I Artikkel 1 fant vi at tilskudd med ALCAR økte nivåene av høy-energi fosfater i 
hjernebarken til mus, noe som tyder på økt energitilgjengelighet. I begge 
hjerneområder senket ALCAR forbruket av glukose vist ved økte nivåer av glukose 
og reduserte nivåer av [3-13C]laktat. Videre fant vi at ALCAR økte konsentrasjonene 
av monoaminene noradrenalin i HF og serotonin i hjernebarken. Disse funnene er 
særlig interessante i forhold til en potensiell antidepressiv virkning av ALCAR. 
I artikkel 2 og 3 demonstrerte vi metabolske endringer i epileptiske mus som 
likner på funnene som er rapportert hos mennesker med TLE, deriblant lavere 
konsentrasjon av glutamat og mitokondriell dysfunksjon i HF. Vi viste også at 
omsetningen av viktige metabolitter som tilhører eller er derivert fra sitronsyresyklus 
var nedsatt i begge hjerneområder i epileptiske mus, forenlig med en dysfunksjonell 
sitronsyresyklus. Tilskudd med ALCAR påvirket ikke anfallsutviklingen i PTZ 
injiserte mus, men motvirket noen metabolske endringer. 
 viii 
Alt i alt har studiene skaffet ny informasjon om de metabolske endringene i 
hjernen til epileptiske mus og mus behandlet med ALCAR i 25 dager. Funnene vil 
kunne være nyttige for å forbedre diagnostikken og behandlingen av TLE og evaluere 
den potensielle rollen til ALCAR i behandlingen av ulike hjernesykdommer. 
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Summary 
 
Epilepsy is one of the most prevalent neurological diseases in the world and temporal 
lobe epilepsy (TLE) is likely the most common form of epilepsy. The treatment 
strategies for TLE are not satisfactory and as many as 60% of patients with TLE 
become resistant to currently available antiepileptic drugs. Although the condition can 
be effectively treated by surgical resection, social and psychological disabilities of the 
disorder often manifest themselves long before referral to surgery. The mechanisms 
underlying TLE still remain unclear, although accumulating evidence points to 
metabolic dysfunction especially in the hippocampus. By elucidating these metabolic 
alterations, we may reveal new targets for antiepileptic treatment and improve 
diagnostic criteria. In Papers 2 and 3, we investigated brain metabolism in two mouse 
models of TLE, namely the pentylenetetrazole (PTZ) kindling model and the 
pilocarpine status epilepticus model, respectively. Moreover, the antiepileptic efficacy 
of acetyl-l-carnitine (ALCAR) on seizures and metabolism was evaluated in the PTZ 
kindling model. 
ALCAR is a dietary supplement readily available in health food stores abroad but 
not in Norway. It is an endogenous compound involved in the transport of acetyl-
moieties across the mitochondrial membrane. For more than two decades, ALCAR 
has been evaluated as a therapeutic supplement in various brain disorders, and has 
shown beneficial effects in small trials with patients with depressive disorders. In rats, 
single administration of ALCAR increases brain energy availability and protects 
against various neurotoxic insults such as ischemia and oxidative stress. However, 
there has been a lack of studies on the effect of chronic ALCAR administration on 
brain metabolism. In Paper 1, we investigated brain glucose, energy and 
neurotransmitter homeostasis in mice supplemented with ALCAR for 25 days. 
In all three studies constituting this thesis, we obtained detailed maps of the 
metabolic content in the cerebral cortex and hippocampal formation (HF) of mice 
using 1H nuclear magnetic resonance (NMR) spectroscopy and high-pressure liquid 
chromatography. To determine glucose metabolism, we injected mice with 13C 
labeled glucose and evaluated brain extracts using 1H and 13C NMR spectroscopy and 
gas chromatography–mass spectrometry. 
In Paper 1, we found that ALCAR supplementation increased the amounts of 
high-energy phosphates in the cortex of mice, indicating increased energy availability. 
In both brain regions, ALCAR decreased glucose consumption evidenced by 
increased amounts of glucose and decreased amounts of [3-13C]lactate. Furthermore, 
ALCAR increased the concentrations of monoamines noradrenaline in the HF and 
serotonin in cortex. These findings are particularly interesting in relation to a potential 
antidepressive effect of ALCAR. In Papers 2 and 3, we demonstrated metabolic 
alterations in epileptic mice, such as glutamate reduction and mitochondrial 
dysfunction in the HF, partly resembling findings reported in human TLE. Moreover, 
we revealed that the turnover of important metabolites within and derived from 
tricarboxylic acid (TCA) cycle intermediates was decreased in both brain regions, 
 x 
consistent with impaired function of the TCA cycle. ALCAR did not affect seizure 
development in PTZ kindled mice, but attenuated some metabolic alterations. 
Altogether, the studies provide new information about metabolic alterations in the 
brain of epileptic mice and mice treated with ALCAR for 25 days. The findings may 
help improving diagnostics and treatment of TLE and evaluate the possible role of 
ALCAR in treating brain disorders. 
 xi 
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1. Introduction 
 
Diseases of the brain, such as epilepsy, Alzheimer’s disease and depressive disorders, 
have a large prevalence in the population. Not only do they affect the life quality of 
patients and their relatives, but they represent challenging issues for the society as a 
whole. Compared to the other life sciences, research on the brain has suffered from 
inadequate methods for investigating tissue function and pathogenesis, especially in 
the living human brain. Hence the understanding of many brain disorders is in general 
insufficient and treatment is not satisfactory. Indeed, acknowledging these challenges 
posed by brain diseases, President Barack Obama of the United States of America 
announced on April 2nd 2013 the BRAIN (Brain Research through Advancing 
Innovative Neurotechnologies) Initiative (WhiteHouse.gov 2013). The initiative is the 
largest research funding since the Human Genome Project with the preliminary goal 
to invent and refine new technologies to understand the human brain (Markoff and 
Gorman 2013). 
The area of focus in this thesis is brain metabolism, in particular that of glucose, 
amino acids, energy and monoamines. In Paper 1, we aimed to investigate metabolic 
differences in the brain of mice supplemented with acetyl-l-carnitine (ALCAR), a 
potential therapeutic agent in the treatment of various brain disorders. In Paper 2, we 
evaluated the antiepileptic efficacy of ALCAR on seizures and metabolism in the 
pentylenetetrazole (PTZ)-kindling model of temporal lobe epilepsy (TLE) in mice. In 
Paper 3, we aimed to further elucidate metabolic alterations in another model of TLE 
in mice, namely the pilocarpine-status epilepticus (SE) model. The first part of this 
thesis serves as an introduction to basic concepts of brain metabolism, including the 
metabolic interplay between the major cell types of the brain, neurons and astrocytes, 
followed by a review about ALCAR metabolism. Thereafter, I give an introduction to 
epilepsy and TLE including the two animal models of TLE that were used in this 
thesis, and I discuss metabolic alterations in TLE. Next, I go through the different 
methodological procedures that we used, followed by summaries of the papers and 
finally the discussion of our work. 
 
 
1.1. Cell types of the brain 
 
By combining microscopy and various staining methods, researchers of the 19th 
century were able to demonstrate that biological tissue consists of individual cells. 
The procedures were inadequate for visualizing neural tissue, though, which lead to 
the common view that the brain was a net-like structure, i.e., a continuum of cells 
fused together (Langmoen and Apuzzo 2007). After the introduction of the Golgi 
silver-staining method, however, Ramón y Cajal in 1887 convincingly demonstrated 
that the brain consists of several distinct cells (Lopez-Munoz et al 2006). The 
pioneering work of Ramón y Cajal and others laid the framework for the Neuron 
Doctrine, the view that the elementary building blocks and signaling units of the brain 
 2 
are individual neurons, which has been central for all disciplines in neuroscience 
since. The Norwegian explorer, diplomat and scientist Fridtjof Nansen was one of 
these pioneers in neuroscience. After completing his histological studies on neural 
tissue using the Golgi method, he stated in a paper dated 1886, that "no anastomoses 
were observed in the nervous systems of the organisms studied by me that could 
doubtlessly be identified as such” (Whiteley 2006).   
The major cellular components in the brain are neurons and glia, the latter 
compromising astrocytes, microglia, radial glia, ependymal cells and oligodendroglia. 
Along with the microvessels of the brain, neurons and glia are organized into well-
structured units capable of coordinating brain activity with local blood flow and 
blood-brain barrier functions (Abbott et al 2006). In this thesis, only neurons and 
astrocytes will be discussed, since these are the two main participants in brain 
metabolism. Neurons and glia differ widely in function and morphology, although 
they are derived from the same neuroepithelial cells of the embryonic nervous system. 
The traditional view has been that neurons are responsible for the primary function of 
the brain, information processing, whereas glia only support neuronal function. 
However, recent advances suggest a more active role of glia, as will be discussed 
below.  
 
 
1.1.1. Neurons 
 
Neurons are the primary signaling units of the nervous system that are organized in 
networks allowing simultaneous information processing in parallel systems. The 
complex operations require that neurons are able to communicate precisely and 
rapidly with each other over long distances. Three features give neurons these 
abilities: electrochemical excitability, asymmetric morphology and the production and 
release of neurotransmitters (Schwartz et al 2013). First, the fact that neurons are 
electrochemically excitable means that neurons may transform chemical or physical 
stimuli into transient electrical signals. This ability depends on the electrochemical 
difference across the cell membrane, the so-called membrane potential. The 
distribution of positively charged ions on either side of the cell membrane is at rest 
unequal, making the electrical voltage more negative inside than outside the cell. 
Various stimuli may alter the permeability of ions across the membrane via ion 
channels and receptors. If a certain threshold voltage is reached, an all-or-none 
electrical signal termed the action potential is generated. Importantly, the asymmetric 
morphology of neurons ensures unidirectional flow of signals. At one end, neurons 
have receptive dendrites that respond to chemical or physical stimuli via specific 
receptors. If an action potential is generated, it is conveyed to the other side of the 
neuron along the cellular process, the axon, terminating at synapses. Synapses are the 
sites of contact between a neuron and another cell and each neuron is innervated by 
thousands of synapses. The most common synapses are chemical, in which there is a 
separate cleft between the cells. Upon an action potential, vesicular neurotransmitters 
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are secreted into the synaptic cleft from the presynaptic neuron. The neurotransmitters 
cross the synapse and bind to specific receptors on the membrane of the postsynaptic 
neuron. Depending on the type of neurotransmitter and the expression of receptors at 
the post-synaptic membrane the binding elicit a specific response. Evidently, precise 
neurotransmission depends on a finely tuned system for the release and clearance of 
neurotransmitters from the synaptic cleft. Synapses may also be electrical by 
definition, in which gap junctions provide cytoplasmic continuity between cells.  
The classical neurotransmitters include the amino acids glutamate, aspartate, γ-
aminobutyric acid (GABA) and glycine, and the monoamines serotonin, dopamine 
and noradrenaline. Non-classical neurotransmitters include peptides (e.g. substance 
P), growth factors and gases (e.g. nitric oxide and carbon dioxide). The main 
excitatory neurotransmitter is glutamate and the main inhibitory is GABA. Both 
neurotransmitters bind to ionotropic and metabotropic receptors. Binding to 
ionotropic receptors rapidly opens ion gates, whereas binding to metabotropic 
receptors activates second-messenger pathways that influence ion channels in a 
slower fashion. Whereas glutamate and GABA is abundant throughout the brain, the 
monoamine neurotransmitters dopamine, serotonin and noradrenaline are synthesized 
only in small nuclei in the brain stem. However, they may influence the functions of 
several brain regions due to projections throughout the brain. Monoamines mainly act 
on membrane bound G-protein coupled receptors involving second-messenger 
pathways. There is a wide diversity of receptor isoforms and subtypes responding to 
the same neurotransmitter. Moreover, a neuron may respond to several 
neurotransmitters depending on the expression of receptors at the post-synaptic 
membranes. Thus, despite the relatively sparse number of neurotransmitters available, 
neurons produce diverse effects due to the variety of receptors and the integration of 
neurotransmission in space and time.  
 
 
1.1.2. Astrocytes 
 
Like neurons, the population of astrocytes is heterogeneous and can be distinguished 
on the basis of morphology, interactions with the local environment and biochemical, 
physiologic, and pharmacologic characteristics (Seifert et al 2006). Their name 
originates from their star-like shape upon Golgi staining, which is similarly 
reproduced by glial fibrillary acidic protein (GFAP) immunolabeling. However, it has 
become clear that GFAP immunostaining reveals only about 15% of the astrocytic 
domain since numerous fine processes do not express GFAP (Bushong et al 2002). 
Thus, the shape of astrocytes is more properly described as “spongiform”. Roughly, 
there are two main types of astrocytes: protoplasmic astrocytes with numerous fine 
processes found in gray matter and fibrous astrocytes with fewer processes found in 
white matter. Unlike neurons, astrocytes occupy separate domains that overlap 
minimally, only about 5% of the total astrocytic volume (Bushong et al 2002). Within 
their separate domains, end-feet dilatations on astrocytic processes cover capillaries 
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and arterioles, ensheathing more than 99% of the cerebrovascular surface (Takano et 
al 2006). In addition to covering microvasculature, end-feet of protoplasmic 
astrocytes envelop neurons and synapses whereas end-feet of fibrous astrocytes 
contact axons. Thus astrocytes are well positioned to link neuronal activity to blood 
flow and regulate the extracellular milieu. Moreover, astrocytic processes are coupled 
via gap junctions to form large intercellular networks allowing transport of small 
molecules such as K+ or glutamate (Giaume et al 2010).  
Astrocytes provide metabolic support to neurons and are critical for homeostasis 
of the neuronal microenvironment, including clearance of synaptic neurotransmitters 
and control of brain water homeostasis, extracellular K+ concentration and local blood 
flow. Moreover, astrocytes synthesize and send neurotransmitter precursors to 
neurons, as will be discussed below. In the brain, K+ buffering is coupled to the 
regulation of osmotic balance. The inwardly rectifying K+ channel Kir4.1 and the 
water channel aquaporin-4 (AQP4) are colocalized primarily at the astrocytic 
perivascular endfeet (Nagelhus et al 2004). At the synapse, astrocytes clear excessive 
K+ released by neuronal firing that could otherwise interfere with cell signaling and 
they may release K+ at distant sites thus functioning as spatial buffers of K+ 
(Wetherington et al 2008).  
Although astrocytes are not electrically excitable, i.e., they cannot fire action 
potentials, several in vitro studies have demonstrated that astrocytes are chemically 
excitable and may modulate synaptic activity in the brain. Astrocytes possess 
functional neurotransmitter receptors and cultured astrocytes respond to glutamate 
with increases of cytosolic Ca2+ (Cornell-Bell et al 1990). Moreover, intracellular 
elevations of Ca2+ in astrocytes can result in the release of so-called gliotransmitters, 
notably glutamate, ATP and D-serine, which may modulate synaptic activity (Bezzi et 
al 1998; Jourdain et al 2007). Whether gliotransmission is a normally occurring event 
and astrocytes modulate synaptic transmission and plasticity in vivo, however, is still 
debated (Halassa and Haydon 2010; Hamilton and Attwell 2010). 
 
 
1.2. Brain metabolism with emphasis on neuronal – astrocytic 
interactions 
 
The brain is highly protected against physiological fluctuations in the external 
environment by the blood-brain barrier. The blood-brain barrier is formed by 
endothelial cells that line the microvessels of the brain restricting the passage of 
molecules due to tight junctions between adjacent cells. Within the brain, metabolism 
occurs in various compartments referring to the presence of functionally distinct pools 
of given metabolites that are not in rapid equilibrium with each other (Berl 1961). At 
the cellular level, the two main metabolic compartments in the brain are astrocytes 
and neurons. At the subcellular level, compartmentation may result from 
heterogeneity in the distribution of proteins, such as enzymes and transporters, or 
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from variations in morphology, internal physical barriers that limit diffusion, 
mitochondrial heterogeneity and so forth.   
 
1.2.1. Glucose metabolism 
 
The brain is an energetically expensive organ. Although the brain accounts for merely 
2% of the body weight, it is responsible for up to 20% of resting body energy 
consumption (Attwell and Laughlin 2001). The high energy demand is related to cell 
signaling, including generation of action potentials, maintenance of ionic homeostasis 
and glutamate recycling. For the adult mammalian brain, glucose is the main energy 
substrate, whereas the developing brain has a higher usage of monocarboxylic acids 
such as lactate and ketogenic bodies. Driven by the higher glucose concentration in 
plasma than in brain interstitium, glucose crosses the blood-brain barrier and is taken 
up in cells through selective glucose transporters (Vannucci et al 1997). Although 
astrocytic endfeet cover almost the entire blood brain barrier, glucose diffuses 
paracellularly (Barros et al 2007) and evenly distributes between the intra- and 
extracellular space (Pfeuffer et al 2000). It has been estimated that neurons and 
astrocytes take up glucose at an approximately equal fraction (Nehlig et al 2004).  
However, it is shown that astrocytes use only 30% of the acetyl-CoA produced from 
glucose (Hassel et al 1995; Qu et al 2000). When in cytosol, glucose is rapidly 
metabolized to glucose-6-phosphate by hexokinase. Hexokinase activity is the rate-
limiting step for glucose metabolism and the transport of glucose from plasma into 
cells is not saturated under physiological glucose concentrations (Barros et al 2007).  
Glucose-6-phosphate has several possible metabolic fates. It is mainly 
metabolized through glycolysis to yield pyruvate, but may also be converted to 
glycogen to serve as energy storage or be funneled through the pentose phosphate 
pathway (PPP) (McKenna et al 2012). The PPP provides reduced nicotinamide 
adenine dinucleotide phosphate (NADPH) for maintenance of reduced glutathione 
and lipid biosynthesis as well as ribose-5-phosphate for nucleotide synthesis. In the 
cytosol, pyruvate may be reduced to lactate or transaminated to alanine. In 
mitochondria, pyruvate can be transaminated to alanine, carboxylated to oxaloacetate 
by the astrocytic specific enzyme pyruvate carboxylase (PC) (Patel 1974) or 
converted to acetyl-CoA by pyruvate dehydrogenase (PDH; in both neurons and 
astrocytes) (Hertz and Dienel 2002). Acetyl-CoA enters the tricarboxylic acid (TCA) 
cycle via condensation with oxaloacetate to form citrate, which is subsequently 
subjected to a cyclic series of oxidative steps. After one turn of the TCA cycle 
oxaloacetate is re-converted and may subsequently react with a new acetyl-CoA 
molecule and initiate another turn of the cycle. There is neither net synthesis nor net 
degradation of any TCA cycle intermediate during this operation and the sole purpose 
of pyruvate oxidation via acetyl-CoA is energy production. Through glycolysis and 
the TCA cycle, metabolism of glucose results in the reduction of electron carrier 
molecules nicotinamide adenine dinucleotide and flavin adenine dinucleotide. After 
reduction, these electron carrier molecules may transfer their electrons to O2 at the 
 6 
inner mitochondrial membrane in a series of reactions called the electron transport 
chain, driving the phosphorylation of adenosine diphosphate (ADP) to produce 
adenosine-5’-triphosphate (ATP). Complete oxidation of one molecule of glucose 
requires 6 oxygen molecules and yields enough chemical energy to produce a 
maximum of 38 ATP molecules, according to the following equation: C6H12O6 + 6 O2 
→ 6 CO2 + 6 H2O. Under basal physiological conditions, glucose is mainly 
oxidatively metabolized, compatible with an oxygen/glucose index for glucose 
metabolism close to 6 (Madsen et al 1999). Recently it was estimated that energy 
requirements of signaling and non-signaling events in the brain are constant and 
independent of signaling frequency (Hyder et al 2013). The results indicate that there 
is a linear relationship between brain activity levels and increases in blood flow, 
blood volume and oxygen consumption. Moreover, the authors showed that the 
energy requirements are conserved across mammalian species suggesting that early in 
the evolution the mammalian brain optimized the balance between energy 
consumption and information processing at the cellular level. 
 
 
1.2.2. Amino acid metabolism 
 
Amino acid neurotransmitter metabolism is linked to glucose metabolism via the TCA 
cycle intermediates α-ketoglutarate and oxaloacetate. The main excitatory 
neurotransmitter glutamate is synthesized from α-ketoglutarate by glutamic acid 
dehydrogenase or various aminotransferases. Glutamate is either packaged into 
vesicles for neurotransmitter use or added to the pool of metabolic constituents. After 
vesicular release into the synapse glutamate is predominantly taken up by astrocytes 
through excitatory amino acid transporters 1 and 2, maintaining extracellular 
glutamate concentrations thousand-fold lower than inside cells (Danbolt 2001). Rapid 
clearance of glutamate ensures high signal to noise ratio for neurotransmission and 
avoids cell damage due to excessive stimulation (excitotoxicity). When in astrocytes, 
glutamate may enter the TCA cycle through conversion to α-ketoglutarate or be 
converted to the non-excitatory compound glutamine by the astrocyte-specific 
enzyme glutamine synthetase (GS) (Norenberg and Martinez-Hernandez 1979). 
Glutamine in turn is exported and taken up by neurons, where it is deamidated to 
glutamate by phosphate-activated glutaminase, completing the so-called glutamate-
glutamine cycle (Kvamme et al 1988; van den Berg and Garfinkel 1971). The cycle 
serves as a buffer reservoir of the precursor glutamine for the synthesis of glutamate 
(and GABA) and also functions as a ammonia detoxification system in the brain. The 
glutamate–glutamine cycle does not operate stoichimetrically since some glutamate is 
converted to α-ketoglutarate and metabolized in the TCA cycle in both neurons and 
astrocytes. 
GABA is synthesized by decarboxylation from glutamate by glutamic acid 
decarboxylase. Neuronal GABA is either packaged into vesicles for synaptic release 
or enters the TCA cycle after conversion to succinic acid semialdehyde and then 
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succinate by the concerted action of GABA transaminase and succinate semialdehyde 
dehydrogenase (Balazs et al 1970). Unlike glutamate, most GABA is taken up by the 
pre-synaptic neuron and to a lesser extent by the astrocyte (Roberts and Frankel 1950; 
Schousboe et al 2004). Thus GABAergic neurons depend to a lesser degree than 
glutamatergic neurons on astrocytic glutamine, although a GABA-glutamate-
glutamine cycle is still present. See Figure 1 for an overview of the metabolism of 
glutamate, glutamine and GABA in neurons and astrocytes.  
Loss of TCA cycle intermediates occurs via various enzymatic reactions such as 
the conversion of α-ketoglutarate to glutamate. Since not all glutamate released from 
neurons is fully recycled from astrocytes and the blood brain barrier is poorly 
permeable for glutamate and glutamine, there is a need for new synthesis of TCA 
cycle intermediates to maintain energy and amino acid production. The formation of 
deficient TCA cycle intermediates from precursors that are not TCA cycle 
intermediates themselves is called anaplerosis. The main anaplerotic enzyme in the 
brain is PC (Patel 1974), which is localized in astrocytes only (Yu et al 1983). PC 
combines CO2 and pyruvate leading to net synthesis of oxaloacetate. Thus neurons 
depend on re-filling of their TCA cycle by newly synthesized glutamine from 
astrocytes to maintain the synaptic glutamate pool. Other anaplerotic pathways 
include the conversion of pyruvate to malate by malic enzyme, although it operates 
predominantly in the opposite direction in the brain (Patel 1974). 
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Figure 1 Simplified schematic representation of the metabolism of glutamate (GLU), 
glutamine (GLN) and GABA in neurons and astrocytes. GLU is the precursor for 
GABA and GLN. GLU is formed from α-ketoglutarate (α-KG) via either glutamate 
dehydrogenase (GDH) or aspartate aminotransferase (AAT). After vesicular release 
from glutamatergic neurons, synaptic glutamate is predominantly taken up by 
astrocytes. Here glutamate can be converted to glutamine (GLN) by glutamine 
synthetase (GS) or enter the tricarboxylic acid (TCA) cycle via α-KG. GLN is 
subsequently transported back to neurons and reconverted to GLU by phosphate-
activated glutaminase (PAG). GLU is then packaged into vesicles or enter the TCA 
cycle. In GABAergic neurons, GABA is produced from GLU by glutamate 
decarboxylase (GAD). Synaptic GABA is predominantly taken up by neurons. After 
uptake in neurons, GABA may be repackaged into vesicles or enter the TCA cycle via 
the sequential action of GABA transaminase (GABA-T) and succinate semialdehyde 
dehydrogenase (SSADH). In astrocytes, GABA enters the TCA cycle via the GABA-
T/SSADH pathway. Subsequently, the TCA cycle may give rise to glutamate, which 
is converted to glutamine and transported back to the GABAergic neuron, whereupon 
GABA is formed from glutamate. Adapted from McKenna et al (2012). 
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1.3. ALCAR 
 
ALCAR is a common dietary supplement readily available in health food stores 
abroad but not in Norway, claimed to improve energy levels and muscle strength. Due 
to its high tolerability and mild adverse effects in humans, supplementation with 
ALCAR is favorable as medical treatment and has been tried out in various brain 
disorders for more than two decades. There is now evidence for beneficial effects of 
ALCAR in the treatment of patients with depressive disorders and related conditions, 
although the trials have been carried out on small groups only (Martinotti et al 2011; 
Pettegrew and McClure 2002; Soczynska et al 2008; Zanardi and Smeraldi 2006). 
The results from trials with Alzheimer’s disease have been conflicting, and a 
Cochrane metaanalysis found no convincing effects (Hudson and Tabet 2003). 
Moreover, ALCAR is marketed for the treatment of peripheral neuropathies 
associated with diabetes and HIV (Evans et al 2008; Hart et al 2004; Youle et al 
2007). 
ALCAR is the short-chain ester of l-carnitine, an endogenous compound present 
in all mammalian tissue (Bremer 1983). L-carnitine is mainly acquired through the 
diet, but may also be synthesized in vivo from the precursors lysine and methionine, 
mostly in the liver and kidney (Rebouche 2004). The main physiological role of the 
carnitine system is to facilitate ß-oxidation by transporting acyl-moieties from fatty 
acids across the mitochondrial membrane (Bartlett and Eaton 2004). Although the 
brain mainly relies on glucose as energy substrate, the carnitine system is present in 
the brain and metabolism of fatty acids can account for 20% of oxidative brain energy 
production in adult rats (Ebert et al 2003). 
The concentrations of ALCAR in plasma and CSF increase after oral 
administration, and the compound is easily transported across the blood-brain barrier 
primarily via the organic cation/carnitine transporter OCTN2 (Kido et al 2001; 
Parnetti et al 1992). Moreover, carnitine transporters from the OCTN family are 
present on both neurons and astrocytes (Januszewicz et al 2009; Januszewicz et al 
2010). The reversible transfer of the acetyl moiety from carnitine to free CoA is 
catalyzed by the enzyme carnitine acetyltransferase, which is located on the inner 
mitochondrial membrane as well as in the endoplasmic reticulum and peroxisomes 
(Bieber 1988). See Figure 2 for a simplified overview of ALCAR metabolism in 
relation to glucose metabolism in a cell. 
The metabolic fate of ALCAR has been thoroughly investigated in the rodent 
brain. The acetyl moiety of ALCAR readily enters the acetyl-CoA pool (Jones et al 
2010), and 60% of radioactivity from [1-14C]ALCAR injected into the lateral rat brain 
ventricle was recovered as 14CO2 in the expirium, indicating oxidative metabolism in 
the TCA cycle (Ricciolini et al 1998). The majority of the remaining radiolabel in the 
brain was incorporated in phospholipids. Recently, Scafidi et al. (2010a) combined 
intraperitoneal injection of [2-13C]ALCAR with ex vivo nuclear magnetic resonance 
(NMR) spectroscopy in juvenile rats. The authors demonstrated that the acetyl moiety 
is utilized for the synthesis of amino acid neurotransmitters via both the neuronal and 
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astrocytic compartments. The acetyl-moiety of ALCAR may also be utilized for the 
synthesis of acetylcholine (Dolezal and Tucek 1981). 
ALCAR treatment has pronounced effects on cerebral glucose and energy 
metabolism. In rats, autoradiography revealed increased [14C]2-deoxyglucose labeling 
in several brain regions after both single and chronic ALCAR administration (Freo et 
al 2009; Ori et al 2002). Single injection of ALCAR reduced the oxidation of glucose 
and stimulated the synthesis of glycogen (Aureli et al 1998), and increased the 
amount of phosphocreatine and reduced the levels of lactate and free organic 
phosphate in the rat brain (Aureli et al 1990). Moreover, ALCAR improved the 
neurological outcome in various animal models of ischemia accompanied by 
restoration of aerobic energy metabolism, underlining the positive effects of ALCAR 
on brain energy homeostasis (Aureli et al 1994; Rosenthal et al 1992; Scafidi et al 
2010b). 
Single administration of ALCAR affects numerous neurotransmitter systems in 
the rat brain (Tempesta et al 1985; Toth et al 1993). Single administration of ALCAR 
before injection of 3,4-methylenedioxymethamphetamine (ecstasy) to rats prevented 
loss of serotonin in various brain regions (Alves et al 2009). In controls, the only 
effect of ALCAR pretreatment was increased content of the serotonin metabolite 5-
hydroxyindoleacetic acid, but not serotonin, in one of six investigated brain regions, 
namely the prefrontal cortex. In a model of attention deficit hyperactive disorder, 
chronic ALCAR treatment normalized the level of noradrenaline and the serotonin 
turnover ratio in specific brain regions (Adriani et al 2004). In normal young rats the 
only change was an increased serotonin turnover ratio in the cingulate cortex.  
Moreover, the acetyl-moiety of ALCAR is readily available for transacetylation 
of functional groups on amino acids, which could potentially modify protein structure 
and activity (Pettegrew et al 2000). Other neurobiological effects of ALCAR include 
modulation of membrane composition and neurotrophic factors (Jones et al 2010; 
Pettegrew et al 2000). Finally, ALCAR protects against neurotoxic insults such as 
exposure to glutamate and amyloid-ß, and has both antioxidant and anti-apoptotic 
properties (Forloni et al 1994; Ishii et al 2000; Liu et al 1993). 
In conclusion, the effects of exogenously administered ALCAR on brain 
metabolism have been extensively studied, but mostly in rats after single exposure. 
The acetyl-moiety of ALCAR readily enters the acetyl-CoA pool and may be utilized 
for the generation of energy and synthesis of neurotransmitters. Moreover, single 
administration of ALCAR has been shown to alter the content and release of various 
neurotransmitters in several brain regions. 
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Figure 2 Simplified overview of acetyl-l-carnitine (ALCAR) metabolism in relation 
to glucose metabolism in a cell. The reversible transfer of the acetyl moiety from 
carnitine to free CoA is catalyzed by the enzyme carnitine acetyltransferase (CAT)
located on the inner mitochondrial membrane. Acetyl-CoA from ALCAR enters the 
acetyl-CoA pool and can be incorporated into the TCA cycle. 
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2. Epilepsy 
 
Epilepsy is the second most common neurological disorder after stroke (Porter 1993), 
affecting about 65 million persons worldwide (Thurman et al 2011). As early as about 
400 BC it was proposed in the Hippocratic writings that seizures originates from the 
brain, but the link was not properly established until the mid 19th century by John 
Hughlings Jackson (Eadie 1995). Since then epileptology has endured a rapid 
development in parallel with seminal discoveries in neuroscience.  
Epilepsy is a disorder of the brain characterized by repetitively occurring seizures 
(Fisher et al 2005). The disorder includes several subtypes with distinct phenotypes 
and pathophysiologies that are classified by etiology into symptomatic (secondary to 
another disease, e.g. cancer or brain insult), idiopathic (arises from itself) and 
cryptogenic (undetermined etiology, probably symptomatic) (Engel 1996). Basically, 
the epileptic brain exists in two functional states: the ictal state during a seizure and 
the longer interictal state in between seizures. The biological basis for the transition 
from the interictal state to a seizure is termed ictogenesis, whereas epileptogenesis 
refers to the underlying processes leading to the development of the chronic phase of 
epilepsy with spontaneous recurrent seizures (Pitkanen and Lukasiuk 2011). Neither 
ictogenesis nor epileptogenesis are well understood today. Current epilepsy treatment 
strategies largely aim at decreasing neuronal excitability and thereby preventing the 
occurrence of seizures. An alternative approach is the targeting of epileptogenesis 
preventing the emergence of the epileptic state. Currently no effective 
antiepileptogenic treatments are available. Approximately one in three epilepsy 
patients are pharmacoresistant and suffer from uncontrollable seizures, emphasizing 
the need for newer treatment strategies (Kwan and Brodie 2000). The consequences 
of uncontrollable epilepsy can be severe including social disability, 
neuropsychological impairment and increased morbidity and mortality (Sperling 
2004). 
Seizures arise from an area termed the epileptic focus and are classified as partial, 
meaning onset in one hemisphere, or generalized, involving both hemispheres, based 
on clinical findings and electroencephalography (Engel 2006). If consciousness is 
altered seizures are described as complex and simple if otherwise. Since epileptic 
seizures are transient disruptions in brain function, the signs and symptoms of 
seizures depend on the localization and function of the affected brain area and the 
degree of spread to other areas. Previously, epileptic seizures have been thought to 
result from massive hypersynchronous activity due to hyperexcitability in large 
numbers of neurons in the brain (Fisher et al 2005). However, a recent study 
demonstrated that neuronal spiking behavior is highly heterogeneous, not 
hypersynchronous, during seizure initiation, indicating complex interplay among 
subsets of neurons (Truccolo et al 2011).  
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2.1. TLE 
 
TLE is the most common form of focal epilepsies and likely the most common form 
of human epilepsies (Engel and Williamson 2008). There are two main types of TLE, 
mesial and lateral. In mesial TLE (MTLE), seizures arise from the inner aspect of the 
temporal lobe, particularly the hippocampus. In lateral TLE, seizures arise from the 
cortical layer on the outer surface of the temporal lobe and may be caused by tumors, 
vascular malformations or cortical dysplasias, among others. MTLE accounts for two-
thirds of the TLEs (Panayiotopoulos 2012). Seizures of MTLE typically begin with an 
aura, a simple partial seizure that may progress with motor and sensory signs and loss 
of consciousness (Engel 2001) (the experience of an aura preceding the loss of 
consciousness during an epileptic seizure is vividly described by Fyodor M. 
Dostoyevsky in an excerpt from the novel “The Idiot” reproduced in the opening 
pages of this thesis). 
Patients with TLE often have a history of an initial precipitating injury (IPI) that 
occurred within the first 4 or 5 years of life (Mathern et al 2002). An IPI is any 
clinically significant medical event with neurological implications occurring prior to 
epilepsy. The most common IPI is complex febrile seizures associated with 67% of 
patients with TLE (French et al 1993). However, since febrile seizures are common in 
the general population, they rarely signify the development of epilepsy, suggesting 
that genetic susceptibility plays a major role in epileptogenesis (Cross 2012). Other 
important IPIs are head trauma, intracerebral infections and SE. Typically there is a 
latency period of a mean 8-9 years between an initial precipitating injury and the 
emergence of spontaneous recurrent seizures (i.e., the epileptogenic period) (Mathern 
et al 2002). As mentioned above, there is no coherent explanation to epileptogenesis, 
and mechanisms include inflammation, neurodegeneration, alterations in the function 
and expression of ion channels and receptors, as well as blood-brain-barrier disruption 
(Pitkanen and Lukasiuk 2011). 
After the first ictal event, patients with TLE usually respond well to antiepileptic 
drugs. However, as many as 60% of patients become pharmacoresistant during the 
course of their condition, in contrast to 20% of patients with primary generalized 
epilepsy (Pati and Alexopoulos 2010). Despite the high degree of drug-resistance 
associated with TLE, the condition is effectively treated by surgical resection (Engel 
2001). The outcome of surgery highly depends on the ability to precisely localize the 
epileptic focus, using non-invasive imaging techniques such as magnetic resonance 
imaging and positron emission tomography. The imaging methods for mapping the 
epileptic brain and the availability of resected human seizure foci have been 
invaluable tools for studying the pathophysiology of TLE. 
A hallmark of hippocampal tissue from TLE patients is sclerosis. Hippocampal 
sclerosis is usually unilateral and refers to loss of neurons, gliosis and network 
reorganization (Blumcke et al 2002). Neuronal loss is typically segmental, affecting 
pyramidal neurons in the CA1, CA3 and CA4 regions of the hippocampal formation 
(HF). The gliosis that accompanies neuronal loss is characterized by hypertrophy of 
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astrocytic cell bodies and processes with altered domain organization and increased 
expression of GFAP rather than an increase in astrocyte number (Oberheim et al 
2008). Moreover, there is axonal and synaptic reorganization such as sprouting of 
axons (mossy fibers) of dentate granule cells that may contribute to hyperexcitable 
circuits. Whether hippocampal sclerosis merely is a consequence of seizures or if it 
represents pre-existing hippocampal abnormalities that dispose to TLE remains 
uncertain. Similar lesions can be found in extrahippocampal structures such as the 
parahippocampal cortices, amygdala and thalamus (Chassoux et al 2004).  
 
 
2.2. Animal models of epilepsy 
 
The use of animal models for reproducing human diseases has played a vital role in 
modern experimental medicine. This has certainly been the case for the research on 
epilepsy, in which animal model studies have contributed vastly to the understanding 
of pathophysiological processes and the development of antiepileptic treatment 
strategies. A wide diversity of models of epilepsy and seizures exists, ranging from 
invertebrate models such as drosophila to non-human primates. Models may be 
induced chemically or electrically or result from genetic manipulation (Sarkisian 
2001). The animal models are characterized into models of seizures or models of 
epilepsy with spontaneously recurrent seizures. Seizure models have been pivotal for 
the discovery and development of antiepileptic drugs and for studying seizure 
mechanisms. Models of epilepsy, on the other hand, better represent the human form 
and offer the opportunity for studying epileptogenesis and the morphological and 
functional disturbances present in the chronic phase of epilepsy. There has been a 
growing concern that acute seizure models may fail to predict efficacy of antiepileptic 
drugs, at least in cases of pharmacoresistant epilepsy and that other models of 
epilepsy should be used more extensively (Loscher 2011). 
For animal models to be applicable to humans there are three criteria that must be 
fulfilled (Coenen and Van Luijtelaar 2003): 1) Face validity: that the behavior and 
appearance of the model and the modeled disorder are similar; 2) Predictive validity: 
that testing of clinically established drugs in the model elicits similar responses as in 
humans. Thus the probability of the model to predict therapeutic responses increases; 
3) Construct validity: that the etiological, neurophysiological, neuropathological and 
genetic hypotheses of the disorder correspond to the theoretical basis of the model. 
The characteristics of TLE can be reproduced in chronic animal models, in 
particular kindling and post-SE animal models. In this thesis, we used a PTZ kindling 
model (Paper 2) and a pilocarpine-SE model (Paper 3). 
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2.2.1. The PTZ kindling model 
 
Kindling is the phenomenon by which repeated application of subconvulsive stimuli 
leads to an incremental increase in seizure susceptibility (Sarkisian 2001). Kindling 
can be induced electrically or chemically and is commonly viewed as a model of 
epileptogenesis and TLE (Bertram 2007; Morimoto et al 2004). The duration, length 
and severity of seizures increase gradually in parallel with decreased seizure threshold 
until a plateau is reached. The change in seizure susceptibility is permanent and 
general, meaning that animals already kindled chemically or electrically develop 
seizures faster and with increased severity if kindled using another agent compared to 
animals not previously kindled (Cain 1981; Cain 1982). This phenomenon is called 
transfer and indicates that electrical and chemical kindling influence similar seizure 
circuitry.  
PTZ was first described as a chemoconvulsant in 1926 (Hildebrandt 1926). The 
compound has been used to generate models of acute seizures (Green and Murray 
1989), the kindling model (Mason and Cooper 1972) and models of chronic 
convulsive seizures (Cremer et al 2009). PTZ appears to mediate its effect through 
binding to the picrotoxin-binding site of the post-synaptic GABAA receptor, which 
may lead to desensitization of the GABA receptor (Kamphuis et al 1990; Macdonald 
and Barker 1978). 
In terms of face validity, the clinical picture of kindling mimics complex partial 
seizures with secondary generalization. Due to cortical involvement it has been 
argued that kindling is closer to human primary generalized epilepsy than TLE 
(Gilbert and Goodman 2006). Kindled animals can develop spontaneous recurrent 
seizures if they are kindled for a prolonged time, although this is not often done 
(Sarkisian 2001). In terms of construct validity, the kindling model does not display a 
latency period, in contrast to that seen in humans after an IPI. It can, however, be 
considered an advantage that epileptogenesis is modeled in a more standard and 
controlled manner in kindling models than in post-SE models (McIntyre et al 2002). 
In terms of construct validity, PTZ kindling mimics TLE by inducing sprouting and 
synaptic reorganization (Cavazos et al 2004; Golarai et al 1992) including neuronal 
loss and gliosis in the hippocampus (Franke and Kittner 2001), although the extent of 
cell death is less compared to post-SE models (Sarkisian 2001). With regard to 
predictive validity, the PTZ kindling model is considered a sensitive screening tool 
for antiepileptic drug efficacy, and identified the effects of levetiracetam, which was 
missed using standard seizure models (Klitgaard et al 1998). 
 
 
2.2.2. The pilocarpine-SE model 
 
In rodents, systemic or intracerebral administration of the cholinergic agonist 
pilocarpine induces SE with the subsequent appearance of spontaneous recurrent 
seizures and neuropathological changes resembling human TLE (Turski et al 1989). 
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Along with the kainate-induced SE model, the pilocarpine-SE model is probably the 
most commonly studied chemically induced model of TLE (Sarkisian 2001). In terms 
of construct validity, the SE model complies with the etiological hypothesis of TLE 
that an initial injury precipitates the development of the disorder. 
Pilocarpine induces SE through activation of muscarinic receptors rapidly 
followed by an imbalance between excitatory and inhibitory transmission probably 
mediated by glutamatergic responses (Priel and Albuquerque 2002). Pilocarpine-SE 
can be blocked by systemic administration of the muscarinic antagonist atropine, but 
atropine has no effect once seizures are initiated (Clifford et al 1987). After SE, there 
is usually a latency period from days to weeks before the emergence of spontaneous 
recurrent seizures (Cavalheiro 1995). The seizures can be classified as partial with or 
without secondary generalization. Electrographically the seizures are characterized by 
paroxysmal hippocampal discharges that rapidly spread to cortical areas (Cavalheiro 
et al 1991). Thus the model complies with criteria for face validity by producing 
limbic seizures in coherence with those seen in TLE. 
Histopathologically, pilocarpine-SE animals share similar phenomena as TLE 
patients (i.e., construct validity). There is extensive neuronal death in the 
hippocampus and adjacent limbic structures accompanied by mossy fiber sprouting, 
synaptic reorganization and gliosis (Borges et al 2003; Motte et al 1998). In terms of 
predictive validity, seizures in the pilocarpine-SE model show similar response to 
antiepileptic drugs as in human TLE (Chakir et al 2006; Glien et al 2002). It is 
considered a weakness that the model can only be induced in adult animals, since 
administration of pilocarpine to young rodents (<P20) does not lead to spontaneous 
recurrent seizures and associated pathological changes (Sarkisian 2001). 
 
 
2.2.3. Metabolic alterations in TLE 
 
Although neuronal activity may be heterogeneous at the onset of seizures and not 
hypersynchronous as previously believed (Truccolo et al 2011), seizures 
fundamentally result from an imbalance between too much excitation and too little 
inhibition. In line with this, currently available antiepileptic drugs are thought to 
decrease excitatory neurotransmission and enhance inhibitory by targeting molecules 
at the excitatory and inhibitory synapses (Bialer and White 2010). However, the 
metabolic picture seen in epileptic tissue is not as straightforward as an imbalance 
between too much glutamate and too little GABA. 
A large number of studies in animals and humans have shown that glutamate and 
glutamate analogues, such as kainic acid and domoic acid, can cause seizures and 
neuronal loss similar to TLE (Ben-Ari 1985; Olney et al 1972; Teitelbaum et al 1990). 
In patients with TLE, in vivo microdialysis revealed 6-fold increase in levels of 
extracellular glutamate within the epileptogenic hippocampus before and during 
seizures (During and Spencer 1993). Interictally, extracellular glutamate was 5-fold 
higher in epileptogenic versus the nonepileptogenic hippocampi (Cavus et al 2005). 
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Moreover, the extracellular glutamate concentration remained markedly elevated for 
at least 20 min after the cessation of seizure activity (During and Spencer 1993), 
suggesting decreased clearance of glutamate from the synapse. Whether uptake of 
glutamate via astrocytic glutamate transporters is dysfunctional in the epileptogenic 
hippocampus remains controversial (Bjornsen et al 2007). Interestingly, the tissue 
content of glutamate was decreased in the epileptogenic versus normal hippocampi in 
patients with TLE, which did not correlate with the extent of neuronal loss (Petroff et 
al 2002b). In epilepsy patients undergoing mesial temporal lobe resection, [2-
13C]glucose was infused in vivo and 13C NMR spectroscopy was performed on brain 
tissue extracts to analyze the resected hippocampi (Petroff et al 2002a). The work 
demonstrated that the rate of glutamate-glutamine cycling in comparison to the 
overall TCA cycle was decreased in patients with hippocampal sclerosis compared to 
normal hippocampi. In another group of patients with TLE, the expression of the 
astrocytic enzyme GS was decreased in the epileptogenic hippocampi, suggesting 
reduced conversion of glutamate to glutamine in astrocytes which could explain the 
accumulation of synaptic glutamate (Eid et al 2004; van der Hel et al 2005). Since the 
glutamate-glutamine cycle is a major contributor to vesicular GABA, downregulation 
of GS could also impair GABAergic inhibition (Liang et al 2006). In two post-SE 
models of TLE in rats investigated by our group, 1H NMR spectroscopy revealed 
decreased hippocampal concentrations of glutamate but normal concentrations of 
GABA (Alvestad et al 2008; Melø et al 2005). The models also displayed alterations 
in the contents of glutamate, GABA and aspartate in cortical regions. 
The level of extracellular GABA was higher during and after seizures in both 
epileptogenic and nonepileptogenic hippocampi in patients with TLE (During and 
Spencer 1993). Interestingly, GABA concentrations were higher in the 
nonepileptogenic hippocampus compared to the epileptogenic. The role of GABA in 
epilepsy is complicated with the demonstration that GABA in some settings may be 
excitatory (Kohling 2002). An in vitro study of brain tissue from patients with TLE 
showed that GABA released by interneurons depolarized excitatory pyramidal 
neurons likely to initiate epileptic discharges (Cohen et al 2002). Moreover, 
spontaneous rhythmic activity in brain slices of human epileptic hippocampi appeared 
to be mediated by GABAergic mechanisms (Schwartzkroin and Haglund 1986). On 
the other hand, inhibition of the TCA cycle of GABAergic neurons using 3-
nitropropionic acid induced seizures in mice (Hassel and Sonnewald 1995). 
During seizure initiation and propagation there are dramatic increases in cerebral 
blood flow and metabolism in the epileptic focus (Kobayashi et al 2006). In contrast, 
functional neuroimaging methods demonstrate hypometabolism of glucose in seizure 
foci and adjacent brain structures interictally (Engel et al 1982; O'Brien et al 1997). 
Neuronal loss does not appear to correlate with the decrease in glucose consumption, 
suggesting that interictal hypometabolism results from dysfunctional mitochondrial 
oxidative and/or glycolytic energy metabolism in epileptic tissue (Dube et al 2001; 
O'Brien et al 1997). In line with this, decreased content of the neuronal marker N-
acetyl aspartate (NAA) is reported in the hippocampi of animals and patients with 
TLE (Alvestad et al 2008; Cendes et al 1994; Melø et al 2005). There seems to be no 
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significant relationship between content of NAA and cell death suggesting that NAA 
loss reflects neuronal metabolic dysfunction rather than neuronal loss (Cohen-Gadol 
et al 2004; Kuzniecky et al 2001; Petroff et al 2002b; Vielhaber et al 2008). 
Moreover, Kann et al. (2005) used fluorescence recordings of nicotinamide adenine 
dinucleotide (phosphate) (NAD(P)H) to evaluate the status of energy metabolism in 
hippocampal slices from TLE patients. The recordings revealed alterations in 
transients of NAD(P)H during neuronal activation compatible with an impairment of 
mitochondrial function (Kann et al 2005). Mitochondrial oxidative stress might also 
be an important contributor to epileptogenesis and reactive oxygen species are 
integral to processes such as excitotoxicity and apoptosis that contribute to seizure-
induced brain damage (Waldbaum and Patel 2010). 
In addition to displaying altered activity of enzymes such as GS, astrocytes may 
contribute to epileptoform activity by releasing glutamate via calcium signaling and 
depolarize local neurons (Tian et al 2005). Interestingly, the ability of astrocytes to 
transmit calcium signaling was reduced by several antiepileptic drugs, including 
valproate, gabapentin and phenytoin. Moreover, several lines of evidence suggest 
impaired K+ redistribution by astrocytes in epileptic tissue that could lower seizure 
threshold and increase likelihood of seizures. As previously described, K+ buffering in 
the brain is coupled to water flux and there is loss of AQP4 channels from astrocytic 
perivascular endfeet in sclerotic hippocampi from patients with TLE (Eid et al 2005). 
Impaired water transport could also lead to swelling of astrocytes in epileptic tissue, 
reducing the extracellular space and strengthening the electric field among tightly 
packed neurons (Wetherington et al 2008). Furthermore, astrocytes may affect 
astrocytic glutamate signaling by releasing inflammatory molecules such as tumor 
necrosis factor α (Wetherington et al 2008). 
In conclusion, altered interplay between GABAergic and glutamatergic 
neurotransmission involving both neurons and astrocytes seems to be vital for 
generating epileptic seizures. Additionally, a considerable number of studies argue for 
an underlying metabolic dysfunction not correlated with neuronal death as an 
important pathophysiological mechanism of TLE. Moreover, disturbed astrocytic 
functions may have implications for epilepsy. 
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3. Methods 
 
 
3.1. Experimental procedures with animals 
 
In all studies mice were used. The animals had free access to food and water and were 
housed in individual cages with a 12-hour light-dark cycle. The animals were adapted 
to these conditions for at least 1 week before being used in the experiments and 
weight and general condition were monitored throughout the study. The animal 
experiments were approved by the local ethic committees and were in accordance 
with national and international guidelines. All efforts were made to minimize the 
suffering and the number of animals in line with modern principles of animal 
research, notably the three R’s (replacement, reduction, refinement) (Russell and 
Burch 1959). For experimentation, the animals were randomly divided in groups and 
the investigators were blinded to their treatment. 
 
 
3.1.1. Papers 1 and 2 
 
Fifty male 4-week-old NMRI mice with an average weight of 25 g were divided in 5 
groups: control, ALCAR-control, PTZ-control, PTZ-ALCAR and PTZ-valproate. The 
two experiments were carried out simultaneously using the same control group. 
 
 
3.1.1.1. ALCAR and valproate supplementation 
 
In Papers 1 and 2, ALCAR and valproate were supplemented in the drinking water for 
4 days before the experimental procedure with PTZ started and continued throughout 
the experiments. Mice subjected to ALCAR treatment received a 1.5 g/L solution of 
ALCAR as drinking water and were allowed to drink ad libitum. ALCAR-control 
mice drank an average of 9.9 ± 0.6 ml per day (calculated by weighing the water 
bottles), which provides a daily ALCAR dose of 496 ± 21 mg/kg body weight. PTZ 
kindled mice supplemented with ALCAR drank an average of 10.1 ± 1.1 ml per day, 
which provides a daily ALCAR dose of 506 ± 36 mg/kg body weight. These doses are 
in accordance with effective ALCAR regimens in previous studies (Hagen et al 2002; 
Mollica et al 2001). In Paper 2, a group of PTZ kindled mice was subjected to 
valproate treatment as positive control. The group received a 3.3 g/L solution of 
valproate as drinking water and was allowed to drink ad libitum. The mice drank an 
average of 8.4 ± 1.4 ml per day, which would provide a daily valproate dose of 920 ± 
48 mg/kg body weight. Healthy control mice drank an average of 7.8 ± 1.2 ml per 
day, whereas PTZ-control mice drank an average of 7.5 ± 1.6 ml water per day. 
At the end of the study, the mean weights of the groups were: control mice: 36.5 ± 
0.7 g; ALCAR mice: 36.6 ± 1.0 g; PTZ-control mice: 34.2 ± 1.6 g; PTZ–ALCAR 
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mice: 35.7 ± 1.1 g; and PTZ–valproate mice: 32.1 ± 0.7 g. The PTZ–valproate mice 
weighed significantly lower than control mice and PTZ–ALCAR mice, when 
comparing the four groups in Paper 2. 
 
 
3.1.1.2. PTZ kindling 
 
PTZ kindling was induced using a similar experimental protocol as Hansen et al. 
(2009). Mice were injected with PTZ (43 mg/kg i.p.) three times a week for three 
weeks. After PTZ injection mice were observed for 30 min for latency to clonic 
convulsions and the severity of convulsions was scored according to a modified 
Racine scale (0 = no response, 1 = 1–3 myoclonic jerks and/or facial twitching and/or 
axial waves going though the body, 2 = more than 3 myoclonic jerks, 3 = clonic 
convulsion with forelimb clonus without loss of postural control, 4 = clonic 
convulsion with loss of postural control, turning to the side and/or rearing, 5 = clonic 
convulsion with loss of righting reflex and/or bouncing, two or more clonic 
convulsions, tonic convulsion or SE) (Hansen et al 2009). The mice were randomized 
before PTZ injections and the observers were blinded to the identity of the animal. 
In the PTZ-control group one mouse died from SE, and one was found moribund. 
One mouse died in the PTZ–ALCAR group during SE. Before the end of the study, 3 
mice from each PTZ-group and the control group were withdrawn from further 
experimentation, as they were intended to be part of another study. 
 
 
3.1.2. Paper 3 
 
7-8-week-old male CD1 mice were used. They were divided in two groups: controls 
and pilocarpine-SE mice. 
 
 
3.1.2.1. The pilocarpine model 
 
15-30 minutes prior to pilocarpine (330-345 mg/kg s.c. in 0.9% saline) injection, 35 
CD1 mice were injected with methylscopalamine (2 mg/kg i.p. in 0.9% NaCl). 
Methylscopalamine is a cholinergic antagonist with limited permeability across the 
blood-brain barrier. Thus, pre-treatment with methylscopalamine minimizes 
peripheral side effects of pilocarpine administration. Twenty-three pilocarpine 
injected mice (66%) experienced behavioral SE as defined by continuous seizure 
activity consisting mainly of whole body continuous clonic seizures, while nine mice 
died and three showed no SE. Only mice exhibiting SE were used further in the 
studies. Ninety minutes after pilocarpine administration, SE was terminated with 
injection of pentobarbital (22.5 mg/kg i.p. in 0.9% NaCl) followed by 1 ml 4% 
dextrose in 0.18% saline (s.c.).  
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All mice were hand-fed moistened cookies and injected with 5% dextrose in 
lactate Ringer's solution twice a day for about three days and thereafter when needed. 
No systematic observations were done to detect spontaneous seizures in mice, but 21 
mice with SE were observed to have handling induced seizures and altered behavior, 
including lack of nest building and all mice had lost 10-20% of weight after SE. Two 
pilocarpine-SE mice died suddenly overnight in their home cages at 10 and 21 days, 
respectively. Autopsies did not reveal causes of death and therefore sudden 
unexplained death in epilepsy or severe seizures are likely. Ten of these mice were 
randomly selected for this study. When video- electroencephalography monitored, all 
male CD1 mice subjected to our pilocarpine-SE model developed spontaneous 
recurrent seizures and/or interictal spikes (Kharatishvili et al 2013) similar to previous 
reports in the same mouse strain (Shibley and Smith 2002). Eleven control mice 
received methylscopalamine and pentobarbital only and 0.9% saline instead of 
pilocarpine. At the end of the study, the mean weights of pilocarpine-SE mice were 
significantly lower compared to controls, 33.92 ± 1.42 g vs. 38.60 ± 1.25 g (p = 
0.024, n = 10 pilocarpine-SE, n = 11 control mice). 
 
 
3.1.3. 13C glucose administration 
 
To be able to determine glucose metabolism, we injected animals with 13C labeled 
glucose 15 min before microwave fixation of the head. In Papers 1 and 2, mice 
received a single bolus of [1-13C]glucose (543 mg/kg i.p.), whereas in Paper 3 a single 
bolus of [1,2-13C]glucose (543 mg/kg i.p.) was given. The time interval of 15 min 
between microwave fixation and 13C glucose injection ensures substantial 13C label 
incorporation in brain metabolites without washout, in line with previous pilot 
experiments using intraperitoneal injection and a study showing that 13C enrichment is 
highest 15 min after intravenous injection of 13C glucose (Hassel et al 1995). 
 
 
3.2. Metabolic analysis 
 
In all studies, we quantified amounts of metabolites in the cerebral cortex and HF 
using high-pressure liquid chromatography (HPLC) and 1H NMR spectroscopy. 
Metabolism of 13C glucose was determined using 1H and 13C NMR spectroscopy, 
except for Paper 3, in which 13C glucose metabolism in the HF was evaluated using 
gas chromatography–mass spectrometry (GC-MS) in addition to 1H NMR 
spectroscopy. In all studies, mice were terminated using microwave fixation. 
Microwave fixation is considered the most humane method to euthanize animals, 
reducing the time of post-mortem metabolism and keeping animal stress and suffering 
to an absolute minimum (AVMA 2013). After microwave fixation, mice were 
decapitated (trunk blood was collected in Paper 3) and cerebral cortices and HF were 
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dissected and stored at -80 °C till extraction. The HF included the dentate gyrus, 
hippocampus proper, subiculum, but not entorhinal cortex. 
To obtain water-soluble molecules for subsequent in vitro analysis, tissue 
samples were extracted using the perchloric acid method (Paper 1 and 2) or the 
methanol-chloroform-water method (Paper 3). Both methods ensure high total tissue 
metabolite yield with low variability (Le Belle et al 2002). In Paper 3, concerns were 
raised that the salt content in samples extracted using the perchloric acid technique 
could decrease spectral quality for our new QCI CryoProbe™ 600MHz ultrashielded 
Plus magnet (Bruker BioSpin GmbH, Rheinstetten, Germany). Therefore, we decided 
to use the methanol-chloroform-water method instead, which does not involve 
precipitation of salt. 
In Paper 3, L-2-Aminobutyric acid (α-ABA) (Sigma Aldrich, St Louis, MO, 
USA) was added as an internal standard for HPLC analysis. All metabolite 
concentrations were corrected for possible tissue loss during the extraction procedure 
using a factor derived from the known amount of α-ABA added to the tissue and the 
actual amount of the final sample quantified by HPLC. 
 
 
3.2.1. 1H- and 13C NMR spectroscopy 
 
NMR spectroscopy is a powerful method for investigating brain metabolism in vivo 
and ex vivo. By exploiting the magnetic moment of nuclei with net spin, NMR 
spectroscopy allows obtaining information about atoms or molecules in a sample of 
interest. Spin is a fundamental property of all elementary particles like mass and 
electrical charge meaning that a particle rotates around its axis. Nuclei with an odd 
number of protons and/or of neutrons possess net spin, and nuclei with net spin have 
magnetic moment. 1H- and 13C are two such nuclei, and in the works included in this 
thesis, 1H- and 13C NMR spectroscopy were used to study metabolism in extracts of 
HF and cerebral cortex of mice. 13C NMR spectroscopy is an excellent tool for 
investigating the flux of 13C labeled substrates through metabolic pathways and for 
distinguishing neuronal-astrocytic interactions in extracts of brain tissue (Rodrigues et 
al 2009; Sonnewald and Kondziella 2003). 
When a sample is subjected to an external magnetic field (B0), nuclei with net spin 
will align with or against the field. The nuclei precess about the magnetic field at a 
certain frequency termed Larmor frequency. The Larmor frequency is the product of 
the gyromagnetic ratio of the nucleus and the magnetic field strength. The nuclei that 
are oriented parallel to the field exists in a lower energy state than those oriented 
against the field, with a surplus of spins existing in the lower energy state compared 
to those in the higher energy state. The number of spins in the lower energy state 
increases with increasing B0. If an electromagnetic pulse B1 with a radio frequency 
that equals the Larmor frequency is applied to the nuclei, the nuclei will absorb the 
energy and transit to a higher energy state. This exchange of energy between two 
different systems with the same frequency is known as resonance. After the transition 
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the nuclei will return to the lower energy state (in a process called relaxation) and re-
emit the electromagnetic radiation. This phenomenon is exploited by NMR 
spectroscopy. Samples are subjected to a large B0 and a radio frequency B1, and when 
B1 is turned off, the tissue transmits an energy signal containing information about the 
tissue. The signal is detected by a receiver coil in the form of a current termed the free 
induction decay, which is converted from the time to frequency domain via the 
mathematical operation Fourier transformation, generating NMR spectra. After 
repeated pulses and relaxations, the signal is accumulated increasing the precision of 
the information. 
The resonance frequency of a nucleus not only depends on the external magnetic 
field applied, but is also slightly affected by the electron density around the nucleus, 
which varies with the type of nuclei and the bonds in the molecule. This phenomenon, 
known as chemical shift, is essential for NMR spectroscopy and makes it possible to 
distinguish between different atoms in the same molecule and between different 
molecules. Importantly, chemical shift is constant if pH and temperature are 
controlled. The magnetic field of a nucleus is also affected by nearby nuclei with net 
spin. This effect is called spin-spin coupling or J-coupling and generates multiplets in 
the NMR spectra. Spin-spin couplings between nearby 13C nuclei (homonuclear 
coupling) cause metabolites with two adjacent 13C nuclei to be represented as 
doublets and not singlets in spectra. Spin-spin couplings between 13C and 1H nuclei 
(heteronuclear coupling) make 13C NMR spectra hard to analyze. This is avoided by 
applying a small powered B1 pulse in the frequencies of 1H during 13C NMR 
experiments, thus decoupling 1H. However, by applying energy to the system the 
intensity of peaks in the 13C NMR spectra increases. When quantifying 13C 
metabolites this phenomenon, termed nuclear Overhauser enhancement (NOE), has to 
be corrected for. Since we do not allow 13C nuclei to fully relax (to spare time, while 
still obtaining valid spectra) we also need to correct 13C integrals for the lack of 
relaxation time. Correction factors were determined from two sets of 13C NMR 
spectra obtained in a pilot study. In the first set, NMR spectra were acquired with a 
standard pulse angle, relaxation delay and acquisition time used in later experiments. 
In the second set, NMR spectra were acquired with a relaxation time of 20 s and 1H 
decoupling initiated only during spectral acquisition, which avoids NOE. Next, 
correction factors for the differential NOE and relaxation effects experienced by the 
reference compound and the compounds were calculated. 
The natural abundance of 13C is only 1.1% of total carbon. Therefore it is of little 
use to apply 13C NMR spectroscopy for studying endogenous metabolites. However, 
the low natural abundance can be exploited by administrating 13C labeled substrates 
and using 13C NMR analysis for determining metabolic pathways and trafficking of 
metabolites between different compartments. In the works included in this thesis we 
used [1-13C]glucose (Papers 1 and 2) and [1,2-13C]glucose (Paper 3). To interpret the 
13C results it is necessary to know the labeling patterns from metabolism of 13C 
labeled glucose. 
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3.2.1.1. Labeling patterns from metabolism of [1-13C]glucose 
(Figure 3A) 
 
[1-13C]glucose is commonly used for studying glucose and amino acid metabolism 
and distinguishing PC activity from that of PDH. Via glycolysis, [1-13C]glucose is 
converted to [3-13C]pyruvate, which can be converted to [3-13C]alanine, [3-13C]lactate 
or enter the TCA cycle via PDH as [2-13C]acetyl-CoA. Metabolism of [2-13C]acetyl-
CoA in the TCA cycle gives rise to [4-13C]α-ketoglutarate, which is a precursor for 
[4-13C]glutamate. Thereafter, [4-13C]glutamate may be converted to [4-13C]glutamine 
by the astrocytic enzyme GS or to [2-13C]GABA in GABAergic neurons. If [4-13C]α-
ketoglutarate is further converted in the TCA cycle, labeled oxaloacetate will be 
formed which can be transaminated to [2-13C]aspartate or [3-13C]aspartate. In 
astrocytes, [3-13C]pyruvate can be converted to [3-13C]oxaloacetate via PC, which can 
lead to the formation of  [2-13C]α-ketoglutarate and eventually [2-13C]glutamate, [2-
13C]glutamine, [4-13C]GABA, and [1-13C]aspartate or [4-13C]aspartate. 
Transamination of [3-13C]oxaloacetate leads to [2-13C]aspartate or [3-13C]aspartate. 
Further cycling of labeled metabolites gives rise to different labeling patterns in 
amino acids. 
 
 
3.2.1.2. Labeling patterns from metabolism of [1,2-13C]glucose 
(Figure 3B) 
 
In Paper 3, we injected mice with [1,2-13C]glucose to obtain information about the 
PPP in addition to distinguishing metabolism of 13C labeled pyruvate via PC from that 
of PDH activity. Via glycolysis, [1,2-13C]glucose is metabolized to [2,3-13C]pyruvate, 
which can be converted to [2,3-13C]alanine, [2,3-13C]lactate or enter the TCA cycle 
via PDH as [1,2-13C]acetyl-CoA. Metabolism of [1,2-13C]acetyl-CoA in the TCA 
cycle gives rise to [4,5-13C]α-ketoglutarate, which is a precursor for [4,5-
13C]glutamate. Thereafter, [4,5-13C]glutamate may be converted to [4,5-13C]glutamine 
by the astrocytic enzyme GS or to [1,2-13C]GABA in GABAergic neurons. In 
astrocytes, [2,3-13C]pyruvate can be converted to [2,3-13C]oxaloacetate via PC, which 
can lead to the formation of [2,3-13C]α-ketoglutarate and eventually [2,3-
13C]glutamate, [2,3-13C]glutamine and [3,4-13C]GABA. Transamination of [2,3-
13C]oxaloacetate leads to [2,3-13C]aspartate (not depicted in the figure). If [2,3-13C]α-
ketoglutarate and [4,5-13C]α-ketoglutarate is further metabolized in the TCA cycle, 
labeled oxaloacetate will be formed which can be transaminated to [1,2-13C]aspartate 
or [3,4-13C]aspartate. Further cycling of labeled metabolites gives rise to different 
labeling patterns in amino acids. 
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Figure 3 Simplified schematic representation of labeling patterns from A) [1-
13C]glucose and B) [1,2-13C]glucose. Only the first turn of the TCA cycle is 
illustrated. Black circles indicate 13C labeling. 13C labeling from pyruvate carboxylase 
(PC) is indicated by hatched circles. Metabolism of [3-13C]pyruvate via PC leads to 
[3-13C]oxaloacetate, which can be converted to [2-13C]aspartate or [3-13C]aspartate 
(Figure 3A). Metabolism of [1,2-13C]glucose leads to [1,2-13C]aspartate and [3,4-
13C]aspartate labeled from both pyruvate dehydrogenase (PDH) and PC (Figure 3B). 
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3.2.1.3. Experimental setup for 1H and 13C NMR spectroscopy 
 
In Papers 1 and 2, lyophilized samples were dissolved in 200 µL of D2O containing 
0.01% ethylene glycol as an internal standard for quantification. Samples were 
transferred to 5 mm Shigemi NMR microtubes (Shigemi Inc., Allison Park, PA, 
USA). The HF samples were analyzed using a BRUKER DRX-600 spectrometer 
(BRUKER Analytik GmbH, Rheinstetten, Germany), while the cortex samples were 
analyzed using a BRUKER DRX-500 spectrometer. The spectra were recorded at 25° 
C. 1H NMR spectra were acquired on the same instruments with the following 
parameters: pulse angle of 90°, spectral width of 32 K data points and the number of 
scans was 128 and 1024 for cortical and hippocampal extracts respectively. The 
acquisition time was 1.36 s and relaxation delay was 10 s. Water suppression was 
achieved by applying a low-power pre-saturation pulse at the water frequency. Proton 
decoupled 13C NMR spectra were obtained using a 30° pulse angle and 30 kHz 
spectral width with 64 K data points employing an acquisition time of 1.08 s and a 
relaxation delay of 0.5 s. The number of scans needed to obtain an appropriate signal 
to noise ratio was typically 25 000 for the cortex samples and 35 000 for the HF 
samples. Relevant peaks in the spectra were identified and integrated using 
XWINNMR software (BRUKER BioSpin GmbH, Rheinstetten, Germany).  
In Paper 3, lyophilized samples were dissolved in 120 µl of D2O (99.9%; 
Cambridge Isotope Laboratories) containing 0.10% ethylene glycol (Merck, 
Darmstad, Germany) and 0.29 g/L 2,2,3.3-d(4)-3-(Trimethylsilyl)propionic acid 
sodium salt (TSP) (98%; Alfa Aesar, Karlsruhe, Germany) as internal standards for 
quantification. Samples were transferred to SampleJet tubes (3.0x103.5 mm) for 
insertion into the SampleJet autosampler (Bruker BioSpin GmbH, Rheinstetten, 
Germany). All samples were analyzed using a QCI CryoProbe™ 600MHz 
ultrashielded Plus magnet (Bruker BioSpin GmbH). 1H and 13C spectra were recorded 
at 20 °C. 1H NMR spectra were acquired with the following parameters: pulse angle 
of 90°, acquisition time of 2.66 seconds and relaxation delay of 10 seconds. The 
number of scans was 256. Proton decoupled 13C NMR spectra were acquired with the 
following parameters: pulse angle of 30°, acquisition time of 1.65 seconds and a 
relaxation delay of 0.5 seconds, 30 kHz spectral width with 98 K data points. The 
number of scans needed to obtain appropriate signal to noise ratios were between 
20 000 – 40 000 (adjusted for sample weight). Relevant peaks in the spectra were 
identified and then integrated using TopSpin™ 3.0 software (Bruker BioSpin GmbH). 
For a typical 13C spectrum see Figure 3. 
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Figure 4 Typical 13C NMR spectrum of a cerebral cortex extract from a mouse 
subjected to pilocarpine-SE and injected with [1,2-13C]glucose 3.5-4 weeks later. 
Monolabeled metabolites give rise to singlets whereas double-labeled metabolites 
give rise to two peaks on either side of the singlet. It should be noted that the peaks of 
creatine, taurine and N-acetyl aspartate represent natural abundance of 13C. Peak 
assignment: 1: [2-13C]creatine; 2: [3-13C]aspartate and [3,4-13C]aspartate; 3: [2-
13C]taurine; 4: [2-13C]GABA and [1,2-13C]GABA; 5: [4-13C]glutamate and [4,5-
13C]glutamate; 6: [4-13C]glutamine and [4,5-13C]glutamine; 7: [3-13C]glutamate and 
[2,3-13C]glutamate; 8: [3-13C]glutamine and [2,3-13C]glutamine; 9: [3-13C]GABA and 
[3,4-13C]GABA; 10: [6-13C]N-acetyl aspartate; 11: [3-13C]lactate and [2,3-13C]lactate. 
3.2.1.4. Quantification of metabolites from 1H and 13C NMR 
spectra 
The total amounts and 13C labeling of metabolites were quantified from the integrals 
of the peak areas using internal standards. In Papers 1 and 2, ethylene glycol was used 
as internal standard in both 1H and 13C spectra, whereas in Paper 3, TSP was used as 
internal standard in 1H spectra and ethylene glycol in 13C spectra. Integrals from 1H 
spectra were corrected for number of protons constituting the peak. Integrals from 13C 
spectra were corrected for NOE and relaxation effects relative to the internal standard, 
and were corrected for the 1.1% natural abundance of 13C using the data obtained 
from 1H NMR spectroscopy or HPLC. When the metabolite was double-labeled, 13C 
natural abundance was calculated as 1.1% x 1.1% of total metabolite amount. In 
Paper 3, all concentrations were corrected for possible tissue loss during the 
extraction procedure using a factor derived from the known amount of α-ABA added 
to the tissue and the actual amount of the final sample quantified by HPLC. 
 28 
 
3.2.2. HPLC 
 
HPLC is a technique that separates and quantifies a mixture of compounds. The 
compounds are dissolved in a liquid mobile phase and pumped through a column 
containing the stationary phase. Depending on the affinity of the compounds to the 
column material and the mobile phase, the time to move through the stationary phase 
differs. A detector at the other side of the column detects the compounds at their 
specific retention times. 
 
 
3.2.2.1. Experimental setup of HPLC 
 
To determine the total amounts of amino acids the samples were analyzed using a 
Hewlett Packard 1100 System (Agilent Technologies, Santa Clara, CA, USA) with 
fluorescence detection, after derivatization with o-phthaldialdehyde. The components 
were separated with a ZORBAX SB-C18 (4.6 x 150 mm, 3.5 micron) column from 
Agilent using 50 mM sodium phosphate buffer (pH 5.9) with 2.5% tetrahydrofurane 
and methanol (98.75%) with tetrahydrofurane (1.25%) as eluents. Compounds were 
quantified by comparison with a standard curve derived from a standard solution of 
metabolites run repeatedly with 15 samples intervals. 
In Papers 1 and 2, we determined the total amounts of monoamines and acid 
metabolites using an Agilent 1200 system (Agilent, USA) with an electrochemical 
detector (Coulochem III, ESA, USA). The components were separated with an Eclips 
XDB-C18 column (4.6x150 mm, 5 micron, Agilent) with an aqueous mobile phase 
(0.90 mL/min) containing 90 mM NaH2PO4, 50 mM citric acid, 0.1 mM EDTA, 0.5 
mM octanesulfonic acid and 7% methanol solution. The amounts of monoamines 
were quantified by comparison with a standard curve derived from standard solutions 
of monoamines run repeatedly after every 15 samples. 
 
 
3.2.3. GC-MS 
 
GC-MS was applied in Paper 3 to analyze the percent labeling incorporated from 
[1,2-13C]glucose into amino acids in hippocampal extracts. In analogy to HPLC, 
compounds are separated according to their affinity to the column material and the 
mobile phase, in this case helium. Next, molecules are shattered into ionized 
fragments and detected according to their mass to charge ratio by a mass 
spectrometer. 
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3.2.3.1. Experimental setup of GC-MS 
 
Aliquots of the samples were dissolved in 0.05 M HCl, followed by lyophilization. 
Organic acids and amino acids were extracted into an organic phase of ethanol and 
benzene, dried under air and reconstituted in N,N-dimethylformamide (Sigma 
Aldrich) before derivatization with N-Methyl-N-(t-
butyldimethylsilyl)trifluoroacetamide in 1% t-butyldimethylchlorosilane (both Regis 
Technologies Inc., Morton Grove, IL, USA). Compounds were analyzed with an 
Agilent 6890N gas chromatograph linked to an Agilent 5975B mass spectrometer 
with an electron ionization source. Results for metabolites were corrected for natural 
abundance of 13C using standard solutions that were acquired concurrently with the 
samples. 
 
 
3.3. Statistics 
 
In all studies, the number of samples for each group varied between analytical 
methods due to experimental errors. 
 
Paper 1: Statistical analysis was performed using the 2-tailed unpaired Student’s t-
test, and p ≤ 0.05 was regarded as significant. Data are represented as mean ± SD. 
Paper 2: Statistical analysis of metabolites was performed using an one-way 
ANOVA followed by a least significant difference post-hoc test, and p < 0.05 was 
regarded as significant. Data of metabolites are represented as mean ± SEM. Analysis 
of seizure severity and latency was performed using a Kruskal-Wallis test 
(nonparametric ANOVA) followed by Mann-Whitney U test. Severity and latency 
data are represented as mean ± SEM. 
Paper 3: Statistical analysis was performed using the 2-tailed unpaired Student’s t-
test, and p < 0.05 was regarded as significant. Data are represented as mean ± SEM. 
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4. Synopsis of papers 
 
 
4.1. Paper 1 
 
Smeland O*, Meisingset T*, Borges K, Sonnewald U 
Dietary supplementation with acetyl-L-carnitine improves brain energy metabolism in 
healthy mice and increases noradrenaline and serotonin content 
Neurochemistry International, 2012 Jul, vol 61 (1) p 100-107, * Joint first authors 
 
Aims: ALCAR has been tried out as a therapeutic supplement in various brain 
disorders for more than two decades. Until now, the effects of ALCAR on brain 
metabolism have mainly been studied after acute administration in rats. We aimed to 
perform a comprehensive analysis of glucose, energy, amino acid and monoamine 
neurotransmitter metabolism after continuous ALCAR supplementation in healthy 
mice. 
Methods: Mice received normal drinking water or drinking water supplemented with 
ALCAR (1.5g/L) for 25 days. 15 min before microwave fixation of the head, animals 
were injected with [1-13C]glucose. Extracts of HF and cerebral cortex were 
investigated using 1H and 13C NMR spectroscopy and HPLC. 
Results: We detected increased amounts of glucose in both HF and cortex of mice 
supplemented with ALCAR. In the HF, [1-13C]glucose content was increased. The 
mean value of cortical [1-13C]glucose amount was increased in ALCAR mice, 
however the  difference between the groups did not reach statistical significance (p = 
0.06). The amount of lactate was not significantly altered by ALCAR administration, 
whereas the levels of [3-13C]lactate were lower in both brain regions investigated. The 
amount of alanine was significantly decreased in the HF, but unaltered in cortex. 
Total amounts and 13C labeling of glutamate and glutamine were unaffected by 
ALCAR treatment in both brain regions investigated, whereas the level of GABA was 
reduced in the HF. The sum of adenosine phosphate (AMP) + ADP + ATP, and the 
levels of phosphocreatine and myo-inositol were all significantly increased in the 
cortex of mice treated with ALCAR. ALCAR administration significantly increased 
the level of hippocampal noradrenaline, whereas the levels in cortex were similar 
compared with control. Finally, the amount of serotonin was significantly increased in 
the cortex of ALCAR-mice.  
Conclusions: We report that chronic ALCAR supplementation in healthy mice 
increased energy availability and decreased glucose consumption in both HF and 
cortex. The findings suggest that ALCAR preferentially enters a TCA cycle 
compartment geared for generation of energy and not amino acid synthesis, since [1-
13C]glucose incorporation into amino acids was unaltered. The increase in levels of 
noradrenaline and serotonin are relevant to previously reported antidepressant effects 
of ALCAR treatment. 
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4.2. Paper 2 
 
Smeland O*, Meisingset T*, Sonnewald U 
Dietary supplementation with acetyl-L-carnitine in seizure treatment of 
pentylenetetrazole kindled mice 
Neurochemistry International, 2012 Sep, vol 61 (4) p 444-454, * Joint first authors 
 
Aims: We hypothesized that ALCAR supplementation could reduce seizures and 
normalize brain metabolism in an animal model of epilepsy. ALCAR has several 
properties that may suggest an antiepileptic effect, such as protection against 
glutamate toxicity (Forloni et al 1994), a favorable effect on energy homeostasis 
(Aureli et al 1990; Aureli et al 1998; Scafidi et al 2010b), and lowering oxidative 
damage and improving mitochondrial function (Liu et al 2002). Moreover, 
pretreatment with l-carnitine before administration of a single convulsive dose of PTZ 
to mice prolonged latency to seizures and reduced the frequency of clonic seizures in 
a dose-dependent manner (Yu et al 1997). We reasoned that ALCAR might mimic the 
anticonvulsive effects of fasting and the ketogenic diet. Since antiquity, fasting has 
been used to control epilepsy and fasting leads to increased production of ketone 
bodies that enter the brain and serve as energy substrates. The ketogenic diet mimics 
the metabolic state of fasting and is anticonvulsive in various forms of epilepsy 
(Hartman and Stafstrom 2012). Moreover, plasma levels of acylcarnitines increase 
during fasting in parallel with ketogenic bodies (Brass and Hoppel 1978), and the 
plasma level of ALCAR is increased in children on the ketogenic diet (Hack et al 
2006). Like the ketogenic diet, ALCAR treatment might serve as an alternative 
energy source to brain cells with altered amino acid homeostasis and decrease seizure 
susceptibility. For our purpose, we wanted to test ALCAR in an animal model of 
epilepsy in which the ketogenic diet was proven anticonvulsive. We decided upon 
using the PTZ kindling model described by Hansen et al (2009). 
Methods: Mice received normal drinking water or drinking water supplemented with 
ALCAR (1.5g/L) or valproate (3.3g/L) for 25 days. The animals were injected with 
PTZ (43 mg/kg) or saline three times a week for three weeks (Hansen et al 2009). 
Upon PTZ injection seizure severity and latency to clonic-tonic seizures were scored. 
15 min before microwave fixation of the head, animals were injected with [1-
13C]glucose. Extracts of HF and cerebral cortex were investigated using 1H and 13C 
NMR spectroscopy and HPLC. 
Results: ALCAR treatment did not affect kindling progression in PTZ kindled mice. 
Valproate, on the other hand, delayed the progression of kindling in the initial stage of 
the experiment evidenced by a significantly lower Racine score at injection day 3. 
Latency to seizures was not affected by either valproate or ALCAR. PTZ kindling 
caused glucose hypometabolism, evidenced by a reduction in both glycolysis and 
TCA cycle turnover in both brain regions investigated, affecting both glutamatergic 
and GABAergic neurons. The amount of glutamate was significantly decreased in the 
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HF of PTZ kindled mice, but not in cortex. ALCAR was able to attenuate PTZ 
induced reductions in lactate and [3-13C]alanine and an increase in dopamine in the 
HF. Moreover, ALCAR normalized the levels of myo-inositol and succinate in the 
cortex. 
Conclusions: ALCAR supplementation did not affect kindling progression in this 
PTZ kindling model in mice. However, ALCAR supplementation normalized some 
metabolic parameters, which may indicate beneficial effects of ALCAR on 
metabolism in the epileptic mouse brain. 
 
 
4.3. Paper 3 
 
Smeland O, Hadera M, McDonald T, Sonnewald U, Borges K 
Brain mitochondrial metabolic dysfunction and glutamate level reduction in the 
pilocarpine model of temporal lobe epilepsy in mice 
Journal of Cerebral Blood Flow and Metabolism, 2013, In print 
 
Aims: The mechanisms underlying the pathogenesis of TLE still remain unclear, 
although increasing evidence points to a disturbance in amino acid neurotransmitter 
homeostasis and energy metabolism. We aimed to investigate glucose, amino acid and 
energy metabolism in the pilocarpine-SE model of TLE in mice. 
Methods: To investigate glucose metabolism, we injected mice 3.5 – 4 weeks after 
SE with [1,2-13C]glucose before microwave fixation of the head. Using 1H and 13C 
NMR spectroscopy, GC-MS and HPLC, we quantified metabolites and 13C labeling in 
extracts of cerebral cortex and HF. 
Results: We detected decreased hippocampal levels of glutamate, glutathione and 
alanine in pilocarpine-SE mice compared to controls. Moreover, the contents of NAA, 
succinate and NAD(P)H were decreased in HF indicating impairment of 
mitochondrial function. Additionally, the reduction in 13C enrichment of hippocampal 
citrate and malate suggests decreased TCA cycle turnover in this region. In cortex, we 
found reduced 13C labeling of glutamate, glutamine and aspartate via the PC and PDH 
pathways, suggesting slower turnover of these amino acids and/or the TCA cycle. 13C 
enrichment of metabolites via the PPP was negligible in both brain areas. 
Conclusions: Altogether the metabolic alterations partly resemble those reported for 
human TLE and rat models of chronic epilepsy, such as glutamate content reduction 
and mitochondrial metabolic dysfunction in the HF. The decreased turnover of 
important metabolites within and derived from TCA cycle intermediates in both brain 
regions are consistent with impaired function of the TCA cycle in mice with 
spontaneous recurrent seizures. Targeting these impaired mitochondrial functions 
might be promising for the treatment of drug-resistant epilepsy. 
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5. Discussion 
 
In the studies constituting this thesis, we obtained neurochemical maps of mice 
supplemented with ALCAR and two mouse models of TLE. The anticonvulsive effect 
of ALCAR was evaluated in the PTZ kindling model and compared to that of 
valproate. Using 1H NMR spectroscopy and HPLC, we investigated metabolism of 
glucose, amino acids, monoamines and energy related metabolites in extracts of 
cerebral cortex and HF. Additionally, 13C NMR spectroscopy and GC-MS were 
performed to provide dynamic pictures of metabolic pathways using 13C labeled 
glucose. 
 
 
5.1. Methodological considerations 
 
In Paper 1, the differences in metabolism between the two groups represent the effect 
of ALCAR supplemented in the drinking water for 25 days. The variability in water 
consumption within the groups was small (9.9 ± 0.6 ml per day in ALCAR-control 
mice and 7.8 ± 1.2 ml per day in control mice) indicating that the administration 
procedure was adequate. Mice received a daily ALCAR dose of about 500 mg/kg in 
accordance with effective regimens in the literature (Hagen et al 2002; Mollica et al 
2001). There are, however, other ways to administer ALCAR to animals. An 
alternative would be to daily inject mice with ALCAR ensuring a more controlled 
design independent of water intake. The advantage of our procedure was to reduce the 
animal stress due to repeated injections, which is why we chose it. A third and 
perhaps preferential option would be to orally administer a finite dose of ALCAR to 
animals, which is a more labor-intensive approach, but avoids the problem of repeated 
injections. Moreover, we should have measured the levels of glucose and ALCAR in 
blood and brain tissue to help interpretation of the metabolic data. 
In Paper 2, the intervention groups were injected with PTZ three times a week for 
three weeks, and two groups were supplemented with either ALCAR or valproate for 
25 days. Importantly, all groups of mice injected with PTZ were fully kindled 
(behavioral stage 4-5) at the final day of the study, meaning that the metabolic data 
represent a time point when all intervention groups had experienced similar seizure 
severity. The control group received saline injections (and experienced no seizures, to 
our knowledge). We did not investigate metabolism in the cortex of PTZ-valproate 
mice but only HF, since HF is considered the region of interest in TLE and valproate 
was primarily included in the experiment as a positive control for seizure evaluation. 
In retrospect, however, it would have been interesting to include the metabolic data 
from this group in the analysis of cortex, particularly since cortex was similarly 
affected as HF in PTZ kindled mice. As described in the methods section, we utilized 
a similar PTZ kindling protocol as Hansen et al. (2009). We used the same mouse 
strain from the same breeding center, and the same PTZ dose, injection regime and 
seizure scoring system. Nevertheless, our PTZ kindled mice experienced considerably 
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higher seizure severity than those reported by Hansen et al. (2009). Moreover, Hansen 
et al. (2009) reported no mortality, whereas two mice died in our PTZ-control group 
and one in the PTZ–ALCAR group, indicating a larger PTZ effect in our mice. It is 
possible that the slight difference in age between the mice in the two studies 
contributed to the difference in seizure susceptibility; our mice were 4 weeks of age at 
the start of kindling compared to 5 weeks in the study of Hansen et al. (2009). Indeed, 
Löscher et al. (1991) pointed out that the seizure threshold after PTZ injection heavily 
relies on the age of animals and may vary even within one week. 
In Paper 3, differences between control and pilocarpine-SE mice represent the 
effect of both epileptogenesis and seizure activity on brain metabolism. It is possible 
that inter-animal variability in the number and severity of seizures contributed to 
variability in metabolic data. However, seizure data was not acquired for each animal. 
In a study using the same mouse model, the mean seizure frequency in the chronic 
phase was 0.5 ± 0.3 per day and all seizures were secondarily generalized (behavioral 
stage 4–5 according to the Racine scale) (Kharatishvili et al 2013). Pilocarpine-SE 
mice received less [1,2-13C]glucose compared to controls due to significantly lower 
body weights. This could lead to decreased enrichment of blood glucose with [1,2-
13C]glucose. However, the 13C enrichment of glucose, lactate and alanine was similar 
in both brain regions indicating that 13C enrichment of glucose in the blood was 
similar between the two groups. 
In previous studies, our group has co-administered [1-13C]glucose with [1,2-
13C]acetate to investigate metabolism in brain tissue using 13C NMR spectroscopy 
(Melø et al 2005; Sonnewald and Kondziella 2003). Acetate is selectively taken up by 
astrocytes (Waniewski and Martin 1998) and co-administration of this substrate gives 
additional information about the astrocytic compartment. In the studies of Papers 1 
and 2 we intended to analyze brain extracts using GC-MS. Since GC-MS does not 
allow for distinguishing the position of carbon atoms within molecules, co-
administration with [1,2-13C]acetate would confound the interpretation of GC-MS 
data and was therefore not performed. In the end, we did not analyze extracts using 
GC-MS, since we were satisfied with our results using NMR spectroscopy. In Paper 
3, we decided to utilize [1,2-13C]glucose to provide information about the PPP. Co-
administration with 13C labeled acetate would confound this information and was 
therefore not done. Unfortunately, PPP activity was below our detection limit in any 
metabolite in the brain regions analyzed. 
 
 
5.2. Glucose metabolism 
 
Recently, Lei et al. (2010) demonstrated that cerebral hypometabolism of glucose is 
marked by increases in cerebral glucose content at the entire range of plasma glucose 
levels. Chronic ALCAR treatment has been shown not to alter serum concentrations 
of glucose (Freo et al 2009) or the uptake of glucose into rat brain slices (Tanaka et al 
2003). In Paper 1, we detected increased levels of glucose in both HF and cortex of 
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mice supplemented with ALCAR. Coupled with the reduced levels of [3-13C]lactate 
in both brain regions, the findings suggest a glucose sparing effect of ALCAR 
treatment decreasing the anaerobic metabolism of glucose.  
In Paper 2, the glucose content of PTZ-control mice was increased in cortex, 
while the increase in hippocampal glucose was not statistically significant (p = 0.14). 
In an experimental protocol similar to ours, PTZ kindled mice displayed increased 
blood glucose levels (Yudkoff et al 2003), whereas injection of a subconvulsive dose 
of PTZ to rats did not affect blood glucose concentrations (Eloqayli et al 2004). 
Higher blood glucose could explain the increase in cerebral glucose content in PTZ-
control mice due to increased concentration gradient. However, the reduction in the 
levels of lactate, [3-13C]lactate and [3-13C]alanine in the HF, and decreased amount of 
[3-13C]lactate in cortex point to cerebral glucose hypometabolism in PTZ-control 
mice. In the HF, ALCAR attenuated the decrease in lactate and [3-13C]alanine 
induced by PTZ kindling, indicating a normalizing effect on pyruvate metabolism in 
this region. ALCAR did not attenuate glucose hypometabolism in cortex. Valproate 
did not affect hippocampal glucose metabolism in PTZ kindled mice.  
We found no differences in the concentrations and 13C enrichments of glucose, 
lactate and alanine in either brain region of pilocarpine-SE mice, in contrast to that 
seen in PTZ kindled mice. The level of blood glucose was unaltered in pilocarpine-SE 
mice. The reason that glucose metabolism seemed to be more affected in PTZ kindled 
mice compared to pilocarpine-SE mice may be due to metabolic differences between 
the models or that PTZ kindled mice were in a post-ictal state of down regulated 
metabolism less than 30 min after final seizure. 
 
 
5.3. Amino acid and neurotransmitter metabolism 
 
In Paper 1, the total amounts and 13C enrichments of amino acids, except for GABA 
in the HF, were unaltered. This indicates that the same amount of total and 13C labeled 
acetyl-CoA from metabolism of [1-13C]glucose entered the TCA cycle responsible for 
labeling amino acids regardless of ALCAR supplementation. In contrast to our 
findings, Aureli et al. (1998) reported that a single bolus of ALCAR prior to [1-
13C]glucose injection decreased “the total amount of 13C label incorporation into 
cerebral amino acids and TCA intermediates” in 6-months-old rats (Aureli et al 
1998). When we did a similar calculation we did not observe a decrease. The 
discrepancy can be explained by a higher contribution of the acetyl moiety from 
ALCAR to amino acid synthesis in the acute compared to chronic treatment, or the 
age or the animal species might have an impact (our mice were 2 months old at the 
end of the study). In 21-22 day-old rats, acute administration of 13C labeled ALCAR 
lead to 13C label incorporation into amino acids derived from the TCA cycle, clearly 
showing that 13C labeled ALCAR may provide 13C labeled acetyl-CoA to the TCA 
cycle (Scafidi et al 2010a). The fact that we found unaltered 13C enrichment of amino 
acids from metabolism of [1-13C]glucose indicates that either 1) the acetyl-moiety of 
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ALCAR was not incorporated into amino acids in our study; 2) the acetyl-moiety of 
ALCAR was incorporated into amino acids replacing another acetyl-CoA source than 
glucose, thus maintaining 13C enrichment of amino acids from metabolism of [1-
13C]glucose; or 3) the acetyl-moiety of ALCAR was incorporated into amino acids 
replacing acetyl-CoA from glucose, but the difference in 13C enrichment of amino 
acids from metabolism of [1-13C]glucose was not sufficient to generate a statistically 
significant result. A combination of the latter two explanations is probably correct, as 
it is unlikely that acetyl-CoA from ALCAR was not incorporated into amino acids in 
our study. 
In Paper 2, we demonstrated that PTZ kindling substantially affected amino acid 
metabolism in both brain regions of mice. The reductions in percent 13C enrichment 
and amount of [4-13C]glutamate, [2-13C]GABA, [4-13C]glutamine and [2-
13C]aspartate in the cortex of PTZ-control mice suggest that the TCA cycle turnover 
was decreased 30 min after the final injection of PTZ. This is supported by a decrease 
in the cortical level of the TCA cycle intermediate succinate. In the HF, the amounts 
of [4-13C]glutamate and [2-13C]GABA were decreased together with a decrease in the 
amount of glutamate. Altogether, the results indicate decreased use of glucose for the 
synthesis of amino acids in both glutamatergic and GABAergic neurons in the early 
post-ictal phase. Interestingly, ALCAR administration seems to specifically affect 
GABA metabolism. In Paper 1, we showed that ALCAR supplementation decreased 
the concentration of GABA in the HF of normal mice (which do not intuitively 
suggest an antiepileptic potential of ALCAR). In Paper 2, ALCAR supplementation 
decreased the 13C enrichment from [1-13C]glucose into GABA in the cortex, 
indicating use of acetyl-CoA from ALCAR for GABA synthesis. This is in 
compliance with the study of Scafidi et al. (2010a) in which it was demonstrated 
higher 13C enrichment in GABA than in glutamate in the mouse forebrain after [2-
13C]ALCAR administration, suggesting preferential metabolism of ALCAR in 
GABAergic neurons. Additionally, intraperitoneal administration of ALCAR for 5 
days increased the content of GABA in substantia nigra of young adult mice (Fariello 
et al 1988). 
Pilocarpine-SE mice displayed a similar amino acid profile as PTZ kindled mice 
in both brain regions. In the HF, the content of glutamate was decreased, while the 
contents of GABA, glutamine and aspartate remained unchanged. In cortex, there 
were no detectable changes in these amino acids. In cortex of pilocarpine-SE mice, 
the level of 13C-labeling in glutamate and glutamine from both PC and PDH pathways 
was decreased. Furthermore, the sum of [1,2-13C]aspartate + [3,4-13C]aspartate, 
labeled both from PC and PDH, was decreased too. Reduced 13C incorporation 
reflects either reduced use of glucose for amino acid synthesis or increased 
degradation of 13C labeled amino acids. Since the total amounts of glutamate, 
glutamine and aspartate were not decreased, it follows that decreased amino acid 
synthesis is probably the cause, accompanied by decreased degradation. In sum, the 
findings in cortex indicate reduced turnover of glutamate, glutamine and aspartate, 
which was not evident in the GABAergic compartment. In the HF of pilocarpine-SE 
mice, however, the 13C enrichment of GABA and aspartate was decreased, whereas 
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that of glutamate and glutamine remained unchanged. Furthermore, GC-MS revealed 
a decrease in 13C enrichment of the TCA cycle intermediates citrate and malate 
suggesting decreased TCA cycle turnover in this region.  
 
 
5.4. Metabolic dysfunction in TLE 
 
One of the main aims of this thesis was to investigate metabolic alterations in 
epileptic tissue to improve our understanding of the mechanisms underlying epilepsy. 
These alterations may serve as biomarkers or new targets for antiepileptic treatment.  
Clearly, the metabolic state in epilepsy cannot be explained by a crude imbalance 
between glutamate and GABA. In both pilocarpine-SE and PTZ kindled mice, we 
found decreased concentrations of hippocampal glutamate, in line with studies of rat 
models of TLE (Alvestad et al 2008; Melø et al 2005) and investigations of 
epileptogenic hippocampi from patients with TLE (Petroff et al 2002b). The 
concentration of hippocampal GABA, however, remained unchanged in all the above-
mentioned studies, suggesting that glutamatergic metabolism is more affected than 
GABAergic metabolism in TLE. It is important to note that these measurements do 
not provide information about the dynamic balance of synaptic neurotransmitter 
content, but only whole tissue content, and cannot address the issue of increased 
extracellular glutamate concentration that is demonstrated prior to and during seizures 
(Cavus et al 2005; During and Spencer 1993; Kanamori and Ross 2011; Wilson et al 
1996). Both the PTZ kindling model and SE models of TLE display neuronal death, 
especially in the HF (Franke and Kittner 2001; Sarkisian 2001). However, glutamate 
reduction does not appear to correlate with neuronal death in human TLE (Petroff et 
al 2002b). Thus glutamate reduction apparently results from metabolic dysfunction 
due altered substrate transport, decreased activity of the TCA cycle and/or various 
mitochondrial enzymes rather than cell death of glutamatergic neurons. 
Melø et al. (2005) reported that metabolism in astrocytes was normal in the 
lithium-pilocarpine rat model since labeling from the astrocyte specific substrate [1,2-
13C]acetate was similar in control and epileptic rats. In neither PTZ kindled mice nor 
pilocarpine-SE mice, we could detect any difference in the total glutamine content in 
the HF despite the reduction in glutamate, in agreement with studies of rat models of 
TLE (Alvestad et al 2008; Melø et al 2005). These results seem to contrast the finding 
that the expression of GS was decreased in the epileptogenic HF of human TLE (Eid 
et al 2004; van der Hel et al 2005), indicating decreased conversion of glutamate to 
glutamine. However, a recent study of pilocarpine-SE rats revealed no quantitative 
changes in the number and volume of astrocytes expressing GS but there was a 
redistribution of the enzyme from distal to proximal astrocyte processes within the 
hippocampus (Papageorgiou et al 2011). Moreover, Melø et al. (2005) reported no 
differences in pyruvate carboxylation in lithium-pilocarpine rats. We, on the other 
hand, showed that 13C-labeling in glutamate and glutamine from both PC and PDH 
pathways was decreased in the cortex of pilocarpine-SE mice. These findings indicate 
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that the decrease in glucose consumption for synthesizing glutamate and glutamine 
affected both the neuronal and astrocytic compartment. Moreover, we detected 
increased content of myo-inositol in the cortex of both pilocarpine-SE and PTZ 
kindled mice. In epilepsy, an increase of myo-inositol is generally considered an 
indication of gliosis. However, we did not detect any change in myo-inositol in the HF 
of epileptic mice, although hippocampal gliosis is a characteristic feature of TLE. 
Since myo-inositol is an important osmolyte in the brain that is particularly enriched 
in astrocytes (Brand et al 1993; Fisher et al 2002), the findings suggest altered water 
homeostasis or astrocytic regulation of myo-inositol in the cortex of epileptic mice 
that was not evident in the HF. 
A characteristic feature of TLE is interictal glucose hypometabolism in the 
hippocampal region, which is routinely detected during presurgical evaluation of the 
epileptic brain using imaging methods such as positron emission tomography 
(O'Brien et al 2008). Similar to findings in the kainic acid rat model (Alvestad et al 
2008), the pilocarpine-SE mice in Paper 3 displayed no differences in the contents of 
glucose, lactate or alanine, except a decreased amount of alanine in the HF, indicating 
normal glucose consumption. However, in both studies the incorporation of 13C 
labeled glucose into amino acids was decreased indicating reduced formation of 
acetyl-CoA from glucose used for amino acid synthesis. In PTZ kindled mice and two 
lithium-pilocarpine rat models of TLE (Dube et al 2001; Melø et al 2005), glucose 
hypometabolism was evident in both hippocampal and cortical regions. Since 
neuronal loss does not appear to correlate with the reduction in glucose consumption 
(Dube et al 2001; O'Brien et al 1997), interictal hypometabolism may result from 
dysfunctional mitochondrial oxidative and/or glycolytic energy metabolism in 
epileptic tissue. Indeed, as described in the introduction, several lines of evidence 
point to mitochondrial dysfunction as part of the metabolic picture in TLE, which our 
investigations in epileptic mice seem to confirm. Similar to the content of glutamate, 
that of NAA was decreased in the HF of pilocarpine-SE mice, in agreement with 
studies of humans with TLE and rat models of TLE (Alvestad et al 2008; Cendes et al 
1994; Melø et al 2005). Similar to glucose hypometabolism, the reduction in NAA 
does not correlate well with the extent of cell death in the epileptogenic hippocampus 
(Cohen-Gadol et al 2004; Kuzniecky et al 2001; Petroff et al 2002b; Vielhaber et al 
2008). Thus it follows that NAA loss should be viewed upon as a marker of neuronal 
metabolic dysfunction in epileptic tissue. In PTZ kindled mice, the content of 
hippocampal NAA was not significantly decreased (p = 0.23). Furthermore, we 
detected decreased 13C enrichment of the TCA cycle intermediates citrate and malate 
in the HF of pilocarpine-SE mice, suggesting decreased TCA cycle turnover in this 
region. Additionally, we found decreased hippocampal contents of the reducing 
nucleotides NAD(P)H and the TCA cycle intermediate succinate in pilocarpine-SE 
mice indicating impairment of mitochondrial function. These findings are in line with 
studies of hippocampal slices from patients with TLE demonstrating dysfunctional 
oxidative and/or glycolytic energy metabolism (Kann et al 2005). In PTZ kindled 
mice, the contents of succinate were unaltered in the HF but decreased in the cortex. 
We detected no significant differences in high-energy metabolites such as 
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phosphocreatine and ATP in either PTZ kindled mice or pilocarpine-SE mice, 
although reduction of these metabolites has been reported in human TLE (Pan et al 
2005). In conclusion, we showed that alterations in pilocarpine-SE mice primarily 
concerned hippocampal metabolites related to mitochondria and the TCA cycle, 
whereas both brain regions were similarly affected in PTZ kindled mice and glucose 
metabolism was particularly altered. Thus, the results may suggest that the 
pilocarpine-SE model is a better model of human TLE than the mouse PTZ kindling 
model.  
 
 
5.5. ALCAR as a therapeutic agent 
 
To our disappointment, ALCAR supplementation did not affect kindling progression 
or latency to seizures in PTZ kindled mice. Valproate, on the other hand, slightly 
delayed the progression of kindling in the initial phase, although the occurrence of 
high severity seizures was not avoided in agreement with the literature (Ohno et al 
2010). The fact that valproate did show an anticonvulsive effect demonstrates that the 
seizure model was valid and a potential anticonvulsive effect of ALCAR could have 
been evident. Despite the lack of anticonvulsive effects, ALCAR treatment produced 
some noteworthy metabolic alterations in PTZ kindled mice such as attenuating 
glucose hypometabolism in the HF. In the cortex, ALCAR did not affect glucose 
metabolism but normalized the level of succinate, which may indicate an 
improvement of mitochondrial metabolism. ALCAR treatment produced no effects on 
high-energy metabolites as it did in healthy mice. Interestingly, ALCAR treatment 
increased the content of cortical myo-inositol in healthy mice, whereas in PTZ kindled 
mice ALCAR attenuated the increase in cortical myo-inositol. These findings suggest 
that ALCAR has an astrocyte specific effect or a modulatory effect on water 
homeostasis. Several studies have shown that dopamine exerts a neuroprotective 
effect in epilepsy (Bozzi et al 2000; Starr 1996). In PTZ kindled mice, we showed 
that ALCAR attenuated the increase in hippocampal dopamine. Whether this finding 
indicates that ALCAR deprived the epileptic tissue of a protective measure or if 
ALCAR prevented the underlying cause for dopamine increase remains unanswered. 
With regard to GABA, ALCAR did not affect the content of this neurotransmitter in 
either brain region of PTZ kindled mice, although ALCAR decreased hippocampal 
GABA content in healthy mice. Similar to ALCAR, valproate slightly affected 
metabolism in PTZ kindled mice. Valproate has been shown to increase the content of 
GABA in several brain regions of rodents (Loscher 2002), however, we could not 
detect any effect of valproate on GABAergic metabolism in the HF of PTZ kindled 
mice. Valproate significantly increased the content of hippocampal glutathione 
indicating improved capacity for cytosolic oxidative reduction in this region. 
Although ALCAR treatment did not produce any anticonvulsive effects in the PTZ 
kindling model in mice, a role of ALCAR in the treatment of epilepsy cannot be 
excluded solely based on this study. ALCAR may be effective in other animal models 
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of epilepsy or in human epilepsies. Nonetheless, the clinical relevance of the 
metabolic alterations produced by ALCAR in epilepsy remains uncertain. 
The fact that ALCAR treatment increases brain energy availability is well 
established in the literature and was reconfirmed in Paper 1. Overall, ALCAR 
supplementation seemed to improve the capacity of the cerebral cortex to buffer and 
provide energy, as evidenced by increased levels of phosphocreatine and the sum of 
AMP+ADP+ATP. The fact that the sum of creatine+phosphocreatine was not 
increased indicates that the increase in phosphocreatine reflects a relatively larger 
reservoir of high-energy phosphates, rather than an increased storage capacity for 
high-energy phosphates provided by creatine. This interpretation is supported by the 
twofold increase in the ratio of phosphocreatine/creatine in the cortex of ALCAR 
mice. Furthermore, the increased amount of the sum of AMP+ADP+ATP reflects 
increased availability of adenosine phosphates. In humans, plasma levels of adenosine 
and ATP increased after ALCAR administration, and the rise in adenosine levels 
preceded that of ATP suggesting an adenosine specific effect by ALCAR (Capecchi 
et al 1997). In the HF of mice supplemented with ALCAR, alterations in energy-
related metabolites were not significantly increased. Altogether, the findings imply 
that the acetyl-moiety of ALCAR is used to produce energy, making the brain less 
dependent on glucose as energy substrate. Since 13C enrichment of amino acids from 
[1-13C]glucose was unaltered by ALCAR supplementation, the findings suggest that 
acetyl-CoA from ALCAR preferentially enters a TCA cycle compartment geared for 
energy production rather than a compartment producing TCA cycle intermediates for 
the synthesis of amino acids, i.e., it appears to be compartmentation of acetyl-CoA 
metabolism in the brain. 
In line with our findings, ALCAR has already been shown to be neuroprotective 
in cerebral conditions with disturbed energy metabolism such as ischemia (Al-Majed 
et al 2006) and traumatic brain injury (Scafidi et al 2010b). Another brain condition in 
which energy metabolism may be dysfunctional is migraine (Schulz et al 2007), and 
due to the effects of ALCAR on cortical high-energy metabolites a trial of ALCAR 
treatment to patients with migraine has been scheduled to begin the fall of 2013 
administered by the Norwegian University of Science and Technology here in 
Trondheim. Moreover, we demonstrated that ALCAR increased the concentrations of 
the monoamines noradrenaline in the HF and serotonin in the cortex of healthy mice. 
These findings are particularly interesting in relation to the potential role of ALCAR 
in the treatment of depression. Current antidepressive drugs are thought to work by 
increasing the synaptic content of serotonin and noradrenaline, and ALCAR was 
beneficial in several small trials of patients with depressive disorders and related 
conditions (Martinotti et al 2011; Pettegrew et al 2002; Soczynska et al 2008; Zanardi 
and Smeraldi 2006). Similar to the present state of antiepileptic treatment, the 
treatment of depression suffers from ineffective drugs with unpleasant side effects and 
novel approaches are needed. Approximately 40% of depressive patients are 
considered pharmacoresistant and all current antidepressants require at least 2–3 
weeks to significantly improve mood (Perroud 2011). Recently, it was demonstrated 
that the antidepressant efficacy of ALCAR in two rat models of depression was 
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associated with epigenetic alterations of the metabotropic glutamate receptor 2 (Nasca 
et al 2013). Importantly, the effects were rapid and long lasting. Thus, ALCAR may 
be a good candidate for antidepressive treatment and more comprehensive 
investigations in humans are warranted (Flight 2013). 
 
 
6. Concluding remarks 
 
Although findings in mouse studies are not necessarily translational to humans, they 
may be highly useful in elucidating basic mechanisms of interventions or disease 
processes that would otherwise be unethical or impractical to extract from human 
studies. Hence, the work presented in this thesis aimed to contribute to the 
understanding of the effect of ALCAR on brain metabolism, extend our knowledge on 
metabolic alterations in TLE, and evaluate the anticonvulsive potential of ALCAR 
treatment. 
In papers 2 and 3, we demonstrated that the metabolic alterations in epileptic 
mice partly resemble those reported in human TLE and rat models of chronic 
epilepsy, such as glutamate level reduction and mitochondrial metabolic dysfunction 
in the HF. Moreover, we revealed that the turnover of important metabolites within 
and derived from the TCA cycle, such as glutamate and GABA, appeared to be 
decreased in both brain regions. These findings are consistent with impaired function 
of the TCA cycle. While seizure activity fundamentally results from dysfunctional 
neurotransmission, metabolic alterations may contribute to and result from seizure 
activity. By addressing these issues, we may uncover new targets for antiepileptic 
treatment and improve diagnostics of epilepsy by establishing new biomarkers. 
In agreement with the literature, we showed that ALCAR supplementation 
increased the availability of energy in the cerebral cortex of mice. Furthermore, we 
propose that ALCAR decreases the consumption of glucose particularly by replacing 
glucose as an energy fuel, since ALCAR did not seem to affect glucose incorporation 
into amino acids. ALCAR did not prove to be an efficient anticonvulsive agent in the 
PTZ kindling model and the role of ALCAR in the treatment of epilepsy remains 
uncertain. However, the metabolic effects of ALCAR on the healthy mouse brain, 
such as increasing the concentrations of noradrenaline and serotonin, show promise 
that ALCAR may be used in the treatment of other brain disorders including 
depression. It will be highly interesting to follow the research on ALCAR in the 
coming years. 
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a b s t r a c t
Acetyl-L-carnitine (ALCAR), the short-chain ester of carnitine, is a common dietary supplement readily
available in health food stores, claimed to improve energy levels and muscle strength. ALCAR has numer-
ous effects on brain and muscle metabolism, protects against neurotoxic insults and may be an effective
treatment for certain forms of depression. However, little is known about the effect of chronic ALCAR sup-
plementation on the brain metabolism of healthy mice. Here, we investigated ALCAR’s effect on cerebral
energy and neurotransmitter metabolism after supplementing the drinking water of mice with ALCAR for
25 days, providing a daily dose of about 0.5 g/kg. Thereafter the animals were injected with [1-13C]glu-
cose, and 13C incorporation into and levels of various metabolites were quantiﬁed in extracts of the hip-
pocampal formation (HF) and cortex using 1H- and 13C-nuclear magnetic resonance (NMR) spectroscopy
and high performance liquid chromatography (HPLC). Increased glucose levels were detected in both
regions together with a decreased amount of [3-13C]lactate, but no alterations in incorporation of 13C
derived from [1-13C]glucose into the amino acids glutamate, GABA and glutamine. These ﬁndings are con-
sistent with decreased metabolism of glucose to lactate but not via the TCA cycle. Higher amounts of the
sum of adenosine nucleotides, phosphocreatine and the phosphocreatine/creatine ratio found in the cor-
tex of ALCAR-treated mice are indicative of increased energy levels. Furthermore, ALCAR supplementa-
tion increased the levels of the neurotransmitters noradrenaline in the HF and serotonin in cortex,
consistent with ALCAR’s potential efﬁcacy for depressive symptoms. Other ALCAR-induced changes
observed included reduced amounts of GABA in the HF and increasedmyo-inositol. In conclusion, chronic
ALCAR supplementation decreased glucose metabolism to lactate, resulted in increased energy metabo-
lite and altered monoamine neurotransmitter levels in the mouse brain.
 2012 Elsevier Ltd. All rights reserved.
1. Introduction
Acetyl-L-carnitine (ALCAR), the short-chain ester of carnitine, is
endogenously produced within mitochondria and peroxisomes and
is involved in the transport of acetyl-moieties across the mem-
branes of these organelles. Therefore, ALCAR can affect lipid, carbo-
hydrate and amino acid, as well as energy metabolism. Since the
early 1990s, much attention has been directed towards the possi-
ble role of ALCAR as a therapeutic agent in aging, disorders of the
brain and its mechanism of action (reviewed by Jones et al.
(2010)). Plasma and CSF concentrations of ALCAR increase after
oral administration, and the compound is transported across the
blood brain barrier by the organic cation/carnitine transporter
OCTN2 (Kido et al., 2001; Parnetti et al., 1992). Carnitine transport-
ers from the OCTN family are present on both neurons and astro-
cytes (Januszewicz et al., 2010, 2009). In rat brain cells, the
acetyl moiety of ALCAR may be used for the biosynthesis of acetyl-
choline (Dolezal and Tucek, 1981), fatty acids (Ricciolini et al.,
1998), and amino acids (Scaﬁdi et al., 2010). Acute ALCAR admin-
istration altered rat brain energy homeostasis by increasing phos-
phocreatine and decreasing lactate and inorganic phosphate levels
(Aureli et al., 1990), stimulating glycogen synthesis (Aureli et al.,
1998), and regionally increasing [14C]2-deoxyglucose labeling
measured by autoradiography in certain brain regions (Ori et al.,
2002). Also, chronic ALCAR increased [14C]2-deoxyglucose labeling
in similar regions of the rat brain (Freo et al., 2009), as well as the
0197-0186/$ - see front matter  2012 Elsevier Ltd. All rights reserved.
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enzyme activities of the sodium potassium and the calcium mag-
nesium ATP-ases by about 30% (Villa et al., 2011).
ALCAR has both antioxidant and anti-apoptotic properties (Ishii
et al., 2000; Liu et al., 1993) and can protect against various neuro-
toxic insults such as excessive glutamate (Forloni et al., 1994) and
amyloid-ß exposure (Virmani et al., 2001). Treatment with ALCAR
improved neurological outcome and energy metabolism in various
animal models of ischemia (Aureli et al., 1994; Rosenthal et al.,
1992) and aging (reviewed by Ames and Liu (2004), Jones et al.
(2010)). In light of such promising ﬁndings in animal models, AL-
CAR has been tested in several clinical trials for various disorders.
Small beneﬁcial clinical effects have been reported for Alzheimer’s
disease in a meta-analysis of double blind randomized controlled
clinical trials (Montgomery et al., 2003). However, a Cochrane re-
view found no convincing effects (Hudson and Tabet, 2003). There
is some evidence from small clinical trials with 24–67 patients that
ALCAR can decrease symptoms of depression in the elderly (Garzya
et al., 1990; Tempesta et al., 1987), ﬁbromyalgia patients (Rossini
et al., 2007) and patients with minimal hepatic encephalopathy
(Malaguarnera et al., 2011).
Most psychiatric treatment is centered on altering monoamine
neurotransmitter homeostasis. There are few reports on the effect
of ALCAR on monoamine metabolism in the brain and they are re-
stricted to rats: acute ALCAR pretreatment before 3,4-methylen-
edioxymethamphetamine (MDMA, ecstasy) injection prevented
mitochondrial damage and also loss of serotonin (5-HT) (Alves
et al., 2009). In the control group acute ALCAR only increased the
level of the serotonin metabolite 5-hydroxyindoleacetic acid (5-
HIAA), but not 5-HT, in one of six investigated brain regions,
namely the prefrontal cortex. In a model of attention deﬁcit hyper-
active disorder, chronic ALCAR treatment restored the noradrena-
line (NA) level and the serotonin turnover ratio (5-HIAA/5-HT) in
speciﬁc brain regions towards the values of normal young rats. In
normal young rats the only change was an increased serotonin
turnover ratio in the cingulate cortex (Adriani et al., 2004).
In summary, there is a lack of studies on the effect of chronic
ALCAR administration on brain metabolism in healthy non-elderly
animals other than rats. Speciﬁcally, this is the case for monoamine
neurotransmitters; information undoubtedly important for under-
standing, evaluating and exploiting chronic ALCAR as a therapeutic
agent. Here, we give a comprehensive metabolomic analysis which
includes; glucose, energy, amino acid and monoamine neurotrans-
mitter metabolism after chronic ALCAR supplementation in mice,
showing for the ﬁrst time increases of noradrenaline and serotonin
levels in the healthy brain.
2. Materials and methods
2.1. Chemicals
[1-13C]glucose (99% 13C) and D2O (99.9%) were purchased from
Cambridge Isotope Laboratories (Woburn, MA, USA), ethylene gly-
col from Merck (Darmstadt, Germany), and acetyl-L-carnitine from
Sigma–Aldrich (St. Louis, MO, USA). All other chemicals were of the
purest grade available from local commercial sources.
2.2. Animals
The Norwegian National Animal Research Authority and the lo-
cal ethics committee approved the experimental procedures. Four-
teen male four week old NMRI mice with an average weight of
25 ± 0.7 g (n = 14; Taconic, Ejby, Denmark) were used in the exper-
iment. Nine mice were used in the intervention group and ﬁve as
controls. All animals were maintained under standard laboratory
conditions on a 12/12 h light/dark cycle (lights on at 7AM), at a
constant temperature of 22 C and a humidity of 60%. Animals
were housed in individual cages with free access to food and water.
The mice were acclimatized to the above conditions for 1 week be-
fore the start of the experiments.
In accordance with previous studies, mice received drinking
water containing ALCAR (1.5 g/L, pH adjusted to 6) ad libitum
(Hagen et al., 2002; Mollica et al., 2001) drinking an average of
9.9 ± 0.6 ml per day (calculated by weighing the water bottles),
which provides a daily ALCAR dose of 496 ± 21 mg/kg body weight.
Control mice receiving ﬁltered tap water drank 7.8 ± 1.2 ml per
day. There was no difference in the weight gain between the
groups. Both groups received saline injections (10 ml/kg i.p.) three
times a week until the last day, due to the fact that they were part
of a bigger study examining the kindling epilepsy model (data not
shown). After 25 days, mice were injected with 543 mg/kg
[1-13C]glucose (i.p., using a 0.3 M solution) and 15 min later were
subjected to microwave ﬁxation of the head at 4 kW for 1.7 s
(Model GA5013, Gerling Applied Engineering, Modesto, CA, USA),
a time point that ensures substantial label incorporation without
washout (Hassel et al., 1995). The brains were removed and the
cortices and the HFs were dissected and stored at 80 C till
extraction. The tissue samples were homogenized in 0.7% per-
chloric acid using a Vibra Cell sonicator (Model VCX 750, Sonics
& Materials, Newtown, CT, USA), potassium perchlorate precipi-
tated by neutralization with 1 M KOH, and supernatants containing
metabolites lyophilized.
2.3. High performance liquid chromatography (HPLC)
To determine the total amount of glutathione, the samples were
analyzed using a Hewlett Packard 1100 System (Agilent Technolo-
gies, Palo Alto, CA, USA) with ﬂuorescence detection, after deriva-
tization with o-phtaldialdehyde and a standard curve derived
from a standard solution of glutathione (Geddes and Wood,
1984). The components were separated with a ZORBAX SB-C18 col-
umn (4.6  150 mm, 3.55 micron, Agilent) using 50 mM sodium
phosphate buffer (pH 5.9) with 2.5% tetrahydrofurane and metha-
nol/tetrahydrofurane (98.75%/1.25%) as eluent.
To quantitate the levels of monoamines NA, 5-HT and dopamine
(DA) and acid metabolites 3,4-dihydroxyphenylacetic acid (DO-
PAC), 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid
(HVA), an Agilent 1200 system with an electrochemical detector
(Coulochem III, ESA, Sunnyvale, CA, USA) was used. Components
were separated with an Eclipse XDB-C18 column (4.6  150 mm,
5 micron, Agilent) with an aqueous mobile phase (0.90 mL/min)
containing 90 mM NaH2PO4, 50 mM citric acid, 0.1 mM EDTA,
0.5 mM octanesulfonic acid and 7% methanol. A standard curve de-
rived from standard solutions of monoamines was run repeatedly
at 15 samples intervals for quantitation.
2.4. 1H- and 13C-nuclear magnetic resonance (NMR) spectroscopy
Lyophilized samples were dissolved in 200 lL D2O containing
0.1% ethylene glycol as an internal standard for quantitation and
re-adjusted to pH 6.5–7.5 Spectra were recorded at 25 C using a
BRUKER DRX-600 for HF and a BRUKER DRX-500 spectrometer
for cortex samples (both BRUKER Analytik GmbH, Rheinstetten,
Germany). 1H-NMR spectra were acquired on the same instru-
ments with the following parameters: pulse angle of 90, spectral
width of 32 K data points and the number of scans was 128 and
1024 for cortical and HF extracts respectively. Acquisition time
was 1.36 s and relaxation delay 10 s. Water suppression was
achieved by applying a low-power pre-saturation pulse at the
water frequency. Proton decoupled 13C-NMR spectra were ob-
tained using a 30 pulse angle and 30 kHz spectral width with
64 K data points employing an acquisition time of 1.08 s and a
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relaxation delay of 0.5 s. The number of scans needed to obtain an
appropriate signal to noise ratio was typically 25,000 for cortex
and 35,000 for HF samples.
Relevant peaks in the spectra were identiﬁed and integrated
using XWIN NMR software (BRUKER BioSpin GmbH, Rheinstetten,
Germany). The total amounts and 13C labeling of metabolites were
quantiﬁed from the areas under the peaks using ethylene glycol as
an internal standard. Correction for natural abundance, nuclear
Overhauser enhancement and relaxation effects relative to the
internal standard were applied to all relevant resonances. For a
typical 13C-NMR spectrum see Fig. 1.
2.5. Labeling patterns from metabolism of [1-13C]glucose
The metabolism of [1-13C]glucose is described in Fig. 2. Via gly-
colysis, [1-13C]glucose is converted to [3-13C]pyruvate, which can
be further converted to [3-13C]alanine, [3-13C]lactate or
[2-13C]acetyl-CoA. [2-13C]acetyl-CoA may enter the TCA cycle
through condensation with oxaloacetate to form citrate. Eventually
the TCA cycle intermediate a-[4-13C]ketoglutarate is formed,
which is the precursor of [4-13C]glutamate. Thereafter, [4-13C]glu-
tamate may be transformed to [4-13C]glutamine in astrocytes due
to the astrocyte speciﬁc localization of glutamine synthetase
(Norenberg and Martinez-Hernandez, 1979) and to [2-13C]GABA
in GABAergic neurons. If a-[4-13C]ketoglutarate is further con-
verted in the TCA cycle it gives rise to different labeling patterns
in these amino acids (Alvestad et al., 2008). In astrocytes
[3-13C]pyruvate can be converted to [3-13C]oxaloacetate via pyru-
vate carboxylase (Patel, 1974) which can lead to the formation of
[2-13C]glutamate, [2-13C]glutamine and [4-13C]GABA.
2.6. Data analysis
Statistics were performed using the 2-tailed unpaired Student’s
t-test, and p 6 0.05 was regarded as signiﬁcant. Data are presented
as mean ± SD. Due to technical problems, the number of analyses
varied between analytical methods.
3. Results
3.1. Glucose-derived and related metabolites
Injection of [1-13C]glucose led to labeling of many metabolites
as shown in a typical 13C-NMR spectrum from cerebral cortex
Fig. 1. Typical 13C-NMR-spectrum of a tissue extract of cerebral cortex from a ALCAR-treated mouse. Peak assignment: 1: creatine C-3; 2: aspartate C-3; 3: taurine C-3; 4:
GABA C-2; 5: glutamate C-4 (peak is truncated); 6: glutamine C-4; 7: glutamate C-3; 8: glutamine C-3.
Fig. 2. Schematic presentation of isotopomers derived from [1-13C]glucose via [2-13C]acetyl-CoA. Black circles indicate 13C labeling from pyruvate dehydrogenase (PDH) and
hatched circle 13C labeling from pyruvate carboxylase (PC). Only the ﬁrst turn of the TCA cycle is illustrated.
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extract of an ALCAR-treated mouse (Fig. 1). Only the part of the
spectrum containing the C-4 and C-3 glutamate and glutamine,
C-2 aspartate and C-2 and C-3 GABA peaks is shown. The labeling
patterns of metabolites labeled from [1-13C]glucose via
[2-13C]acetyl-CoA from the ﬁrst turn of the TCA cycle are depicted
in Fig. 2. The C-2 and C-3 positions are labeled in the second and
subsequent turns of the TCA cycle (not shown).
The total and labeled amounts of glucose, lactate, alanine and
amino acids were quantiﬁed using 1H- and 13C-NMR spectroscopy.
In the HF the total amounts of glucose and alanine were increased
by 43% (p = 0.05) and decreased by 31% (p = 0.004), respectively
after 25 days of ALCAR treatment (Fig. 3). Furthermore, lactate con-
tent in the ALCAR treated group compared to control was decreased
by 38% (p = 0.08). In the cortex the glucose content was increased
by 55 % (p = 0.01), but amounts of lactate and alanine remained un-
changed. The levels of [3-13C]lactate were lower in both brain re-
gions investigated by 63% (p = 0.04) in the HF and 37% (p = 0.04)
in the cortex. Moreover, [1-13C]glucose content was 38% higher in
the HF of mice treated with ALCAR (p = 0.01) and a similar trend
was seen in cortex (22 % increase, p = 0.06). The amounts of
[3-13C]alaninewere not signiﬁcantly changed in either brain region.
Following ALCAR administration the amounts of GABA were sig-
niﬁcantly decreased in the HF by 32 % (p = 0.01), but were un-
changed in the cortex (Fig. 4), consistent with regional speciﬁc
metabolic alterations by ALCAR as previously described (Freo
et al., 2009; Ori et al., 2002). The amounts of glutamate and gluta-
mine were unaffected in both brain regions. The same was true for
the levels of [4-13C]glutamate, [4-13C]glutamine and [2-13C]GABA,
the [1-13C]glucose-derived metabolites labeled in the ﬁrst turn of
the TCA cycle via [2-13C]acetyl-CoA. Consequently, the percent
13C enrichment of glutamate and glutamine was unaltered. The
same was the case for GABA since the individual values for
[2-13C]GABA content in the ALCAR treated animals were smaller
than those in the control group, even though this difference was
not signiﬁcant (p = 0.30). No alterations in the pyruvate carboxyla-
tion to dehydrogenation ratios were observed between control and
ALCAR treated animals (results not shown).
3.2. Other metabolites
ALCAR treatment signiﬁcantly increased the levels of several
energy metabolites in the cortex, such as the sum of adenosine
nucleotides AMP, ADP, and ATP by 23% (p = 0.03), phosphocreatine
by 66% (p = 0.04), and myo-inositol by 30% (p = 0.02, Table 1). The
ratio of phosphocreatine/creatine (PCr/ratio) was about twofold
higher in the cortex of mice treated with ALCAR (p = 0.03). The
amounts of creatine, succinate, glutathione, choline-containing
compounds and N-acetylaspartate (NAA) were unchanged in both
brain regions investigated. The levels of nicotinamide adenine
dinucleotide (NAD) were not quantiﬁable in the HF and were unaf-
fected in the cortex.
3.3. Monoamine neurotransmitters
ALCAR administration resulted in a signiﬁcant 25% increase in
the level of NA in the HF (p = 0.03), but not in cortex (Fig. 5).
A C
B D
Fig. 3. Glucose metabolism in brain extracts of hippocampal formation and cortex from control (white bars) and ALCAR-treated mice (black bars). Levels of glucose, lactate
and alanine quantiﬁed by 1H-NMR spectroscopy (A and B) and [1-13C]glucose, [3-13C]lactate and [3-13C]alanine obtained by 13C-NMR spectroscopy are shown (C and D). Data
represent mean ± SD of four control mice and nine ALCAR-treated mice for hippocampal formation, and ﬁve control mice and nine ALCAR-treated mice for cortex. ⁄p 6 0.05,
⁄⁄⁄ 6 0.005, statistically signiﬁcantly different from control group, analyzed by Student’s t-test.
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Moreover, 5-HT concentrations were signiﬁcantly increased in the
cortex by 20% (p = 0.005), with a similar trend in the HF, although
without statistical signiﬁcance (22%, p = 0.09). The serotonin turn-
over rate (5-HIAA/5-HT) was decreased in the cortex from 0.49 to
0.37 (p = 0.04), a potential reason for the increase in serotonin lev-
els (Table 2). The following parameters measured were not affected
by ALCAR treatment; (1) DA and 5-HIAA amounts in both brain re-
gions and (2) neither DOPAC and HVA levels nor the ratios of DA
metabolites to DA, HVA/DA and DOPAC/DA, measures of DA
turnover, in cerebral cortex. The amounts of DOPAC and HVA in
the HF were below our detection level for quantitation.
4. Discussion
The most important ﬁndings of this work are (1) alterations in
glucose and lactate metabolism, (2) increases in high energy phos-
phates and (3) myo-inositol, as well as (4) increases in the levels of
A C
B D
Fig. 4. Amounts of amino acids glutamate, GABA and glutamine (A and B) and 13C-labeled amino acids derived from [1-13C]glucose (C and D) in brain extracts of hippocampal
formation and cortex from control (white bars) and ALCAR-treated mice (black bars). Data represent mean ± SD of ﬁve control mice and nine ALCAR-treated mice, ⁄⁄p 6 0.01,
statistically signiﬁcantly different from control group.
Table 1
Amounts (lmol/g tissue) of metabolites in brain extracts of hippocampal formation and cortex from control and ALCAR-treated mice.
Hippocampal formation Cortex
Control ALCAR Control ALCAR
AMP + ADP + ATP 1.64 ± 0.97 1.83 ± 1.14 2.48 ± 0.50 3.07 ± 0.35⁄
Creatine 8.64 ± 0.93 8.02 ± 0.96 9.57 ± 2.06 8.52 ± 1.08
Phosphocreatine 1.62 ± 1.20 2.02 ± 0.72 1.15 ± 0.61 1.91 ± 0.59⁄
Creatine + phosphocreatine 10.26 ± 1.18 10.05 ± 0.97 10.72 ± 2.45 10.43 ± 0.74
PCr/Cr ratio 0.19 ± 0.15 0.26 ± 0.11 0.12 ± 0.06 0.23 ± 0.09⁄
NADH n.d. n.d. 0.29 ± 0.07 0.36 ± 0.08
Succinate 0.55 ± 0.28 0.63 ± 0.12 0.41 ± 0.10 0.49 ± 0.18
Glutathione 1.30 ± 0.24 1.35 ± 0.30 1.16 ± 0.15 1.32 ± 0.15
Cholinea 1.72 ± 0.06 1.57 ± 0.18 1.78 ± 0.13 1.82 ± 0.14
Myo-inositol 10.12 ± 2.32 11.04 ± 2.13 5.86 ± 0.80 7.60 ± 1.40⁄
N-acetylaspartate 5.51 ± 0.34 5.50 ± 0.67 7.36 ± 0.50 7.79 ± 0.97
All metabolite levels were quantiﬁed using 1H-NMR spectroscopy, with the exception of glutathione (HPLC) and myo-inositol (13C-NMR spectroscopy). Abbreviations:
Cholinea: choline-containing compounds; NADH: nicotinamide adenine dinucleotide; n.d: not determined; PCr/Cr ratio: phosphocreatine/creatine ratio. Data represent
mean ± SD of ﬁve control mice and nine ALCAR-treated mice, and were analyzed with the Student’s t-test. ⁄p 6 0.05, statistically signiﬁcant difference from control mice.
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some monoamine neurotransmitters in hippocampus and/or cor-
tex after chronic ALCAR supplementation in mice. The implications
of our results are discussed below in relation to previous ﬁndings.
4.1. Glucose metabolism
In this study we found that chronic dietary supplementation
with ALCAR increased the amount of glucose in both cerebral cor-
tex and HF. Similarly, Ori et al. (2002) and Freo et al. (2009) re-
ported that acute and chronic ALCAR administration increased
[14C]2-deoxy-D-glucose labeling in various brain regions. Also, AL-
CAR treatment did not alter serum concentrations of glucose
(Aureli et al., 1998; Freo et al., 2009; Ori et al., 2002) or the uptake
of [18F]ﬂuoro-2-deoxy-D-glucose into rat brain slices (Tanaka et al.,
2003). This indicates that ALCAR does not alter brain glucose up-
take. In agreement with the reported reduced amounts of lactate
in the normal adult and aged rat brain after acute ALCAR treatment
(Aureli et al., 1990), we also found decreased [3-13C]lactate levels
in mice, but no changes in the concentrations of TCA cycle-derived
13C-labeled glutamate, glutamine or GABA. Increased glucose
concentration and unchanged TCA cycle activity have also been ob-
served by Nilsen et al. (2011) in mice with reduced a-ketoglutarate
dehydrogenase complex activity. Taken together our results indi-
cate that ALCAR administration reduced glucose metabolism to
lactate without changing glucose metabolism via the TCA cycle,
which lead to higher brain glucose concentrations. Similarly, acute
ALCAR treatment counteracted production of lactate in rat and dog
models of ischemia (Aureli et al., 1994; Rosenthal et al., 1992).
4.2. Energy metabolites
The levels of the sum of AMP + ADP + ATP, phosphocreatine and
the PCr/Cr ratio were signiﬁcantly increased in the cortex in our
mice supplemented with ALCAR compared to control. The fact that
the sum of creatine + phosphocreatine was unaltered indicates that
the increase in phosphocreatine reﬂects a larger reservoir of high-
energy phosphates. Furthermore, the increased amount of the sum
of AMP + ADP + ATP may reﬂect increased concentration of ATP
(see studies below). We could not distinguish the phosphorylation
state of adenosine due to resonance overlap in the 1H-NMR spectra.
Our ﬁndings are in line with several studies demonstrating that AL-
CAR treatment increased the levels of phosphocreatine and re-
duced the amount of free organic phosphate in the adult and old
rat brain (Aureli et al., 1990), elevated the amounts of phosphocre-
atine and ATP in a rat model of ischemia (Aureli et al., 1994), pre-
vented ATP depletion in neuroblastoma cells exposed to beta-
amyloid (Dhitavat et al., 2002), and ameliorated the decrease of
ATP in rat hippocampus after ischemia (Al-Majed et al., 2006).
Taken together, the data indicate that ALCAR treatment improves
the capacity of the brain to produce high-energy phosphates and
reduces anaerobic glucose metabolism. This potential neuroprotec-
tive ability may prove to be beneﬁcial in conditions with disturbed
energy metabolism.
4.3. Myo-inositol
The level of myo-inositol was increased in the cortex of mice
supplemented with ALCAR in the present study. Likewise, ALCAR
has been shown to prevent myo-inositol depletion in a streptomy-
cin induced rat model of diabetic neuropathy (Nakamura et al.,
1998; Stevens et al., 1996). Myo-inositol is important for the syn-
thesis of PIP2, IP3, DAG and complex signaling phospholipids. If
myo-inositol is increased due to a decreased synthesis of these
molecules, it would have widespread functional consequences. It
is also an important osmolyte in the brain and is the most abun-
dant form of inositol (Fisher et al., 2002). Myo-inositol has been
found to be particularly enriched in astrocytes (Brand et al.,
1993). Thus, the increased content of this metabolite appears to re-
ﬂect an effect of ALCAR on this cell type. The effect on myo-inositol
suggests that ALCAR can have a positive inﬂuence in disorders
where water homeostasis is altered.
4.4. Monoamine neurotransmitters
ALCAR supplementation enhanced the amounts of NA and 5-HT
in healthy mice. An increased level of NA was detected in the HF,
whereas the amount of 5-HT was increased in the cortex, accompa-
nied by a decreased 5-HIAA/5-HT ratio, the latter reﬂecting re-
duced serotonin turnover. It is of interest in this context that NA
increases oxidative metabolism in cultured astrocytes and freshly
dissociated astrocytes express the relevant receptor subtypes
(Hertz et al., 2010). In several small trials, ALCAR was found to
Fig. 5. Amounts (nmol/g tissue) of monoamines and their metabolites in brain
extracts of hippocampal formation and cortex from control (white bars) and ALCAR-
treated mice (black bars) quantiﬁed using HPLC. Abbreviations: Noradrenaline (NA),
3,4-dihydroxyphenylacetic acid (DOPAC), dopamine (DA), 5-hydroxyindoleacetic
acid (5-HIAA), homovanillic acid (HVA), serotonin (5-HT). Data represent mean ± SD
of ﬁve control mice and seven ALCAR-treated mice for hippocampal formation, and
ﬁve control mice and nine ALCAR-treated mice for cortex. ⁄⁄⁄p 6 0.005 statistically
signiﬁcantly different from control group, analyzed with the Student’s t-test.
Table 2
‘‘Turnover’’ of dopamine and serotonin in brain extracts of hippocampal formation
and cortex from control and ALCAR-treated mice.
Hippocampal formation Cortex
Control
(n = 5)
ALCAR
(n = 7)
Control
(n = 5)
ALCAR
(n = 9)
DOPAC/DA n.d. n.d. 0.16 ± 0.04 0.15 ± 0.02
HVA/DA n.d. n.d. 0.15 ± 0.06 0.20 ± 0.04
5-HIAA/5-HT 1.31 ± 0.43 0.98 ± 0.16 0.49 ± 0.09 0.37 ± 0.05⁄
The ratios of monoamine neurotransmitters to their metabolites were calculated as
a measure for their turnover rates calculated using data from HPLC. Abbreviations:
n.d. not determined. Data represent mean ± SD, and were analyzed with the Stu-
dent’s t-test. ⁄p 6 0.05, statistically signiﬁcant difference from control mice.
O.B. Smeland et al. / Neurochemistry International 61 (2012) 100–107 105
be beneﬁcial for patients with depressive disorders and related
conditions (Martinotti et al., 2011; Pettegrew et al., 2002;
Soczynska et al., 2008; Zanardi and Smeraldi, 2006). The reported
increase of 5-HT and NA levels presented here validate further
study of these neurotransmitters, their metabolism and receptors
in relation to ALCAR and depressive disorders, and may provide
rationale for an antidepressant effect of ALCAR.
5. Summary
In conclusion, we report that ALCAR supplementation in healthy
mice resulted in improved energy metabolism and sparing of glu-
cose in both HF and cortex. The amounts of the monoamines NA
and 5-HT were increased in the HF and cortex respectively. These
new insights warrant further studies of ALCAR in clinical settings
especially for diseases known to involve energy deﬁcits or mono-
amine neurotransmitter derangements.
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a b s t r a c t
In spite of the availability of new antiepileptic drugs a considerable number of epilepsy patients still have
pharmacoresistant seizures, and thus there is a need for novel approaches. Acetyl-L-carnitine (ALCAR),
which delivers acetyl units to mitochondria for acetyl-CoA production, has been shown to improve brain
energy homeostasis and protects against various neurotoxic insults. To our knowledge, this is the ﬁrst
study of ALCAR’s effect on metabolism in pentylenetetrazole (PTZ) kindled mice. ALCAR or the commonly
used antiepileptic drug valproate, was added to the drinking water of mice for 25 days, and animals were
injected with PTZ or saline three times a week during the last 21 days. In order to investigate ALCAR’s
effects on glucose metabolism, mice were injected with [1-13C]glucose 15 min prior to microwave ﬁxa-
tion. Brain extracts from cortex and the hippocampal formation (HF) were studied using 1H and 13C
NMR spectroscopy and HPLC. PTZ kindling caused glucose hypometabolism, evidenced by a reduction
in both glycolysis and TCA cycle turnover in both brain regions investigated. Glutamatergic and GABAer-
gic neurons were affected in cortex and HF, but the amount of glutamate was only reduced in HF. Slight
astrocytic involvement could be detected in the cortex. Interestingly, the dopamine content was
increased in the HF. ALCAR attenuated the PTZ induced reduction in [3-13C]alanine and the increase in
dopamine in the HF. However, TCA cycle metabolism was not different from that seen in PTZ kindled ani-
mals. In conclusion, even though ALCAR did not delay the kindling process, it did show some promising
ameliorative effects, worthy of further investigation.
 2012 Elsevier Ltd. All rights reserved.
1. Introduction
Epilepsy is a diverse group of neurologic seizure disorders; the
common denominator being a disposition to excessive and syn-
chronous neuronal activity (Fisher et al., 2005). The life time prev-
alence of seizure is 2–5%, whereas the prevalence of epilepsy is 5–
10 per 1000 in the developed world (Bell and Sander, 2001). After
the ﬁrst unprovoked seizure, 40–50% of patients will experience a
recurrence within a two year time period (Berg, 2008) and about
one-third of epilepsy patients are pharmacoresistant (Pati and
Alexopoulos, 2010) and thus in need of novel therapies.
A reduced ability to utilize glucose is thought to be an impor-
tant feature of the metabolic disturbances caused by seizure activ-
ity (Hagemann et al., 1998; Janigro, 1999). Indeed, ketogenic diet, a
treatment for epilepsy, is believed to exert its effect by providing
an alternative fuel (Hansen et al., 2009; Melo et al., 2005; Yudkoff
et al., 2007). Approximately 50% of children with refractory epi-
lepsy have a signiﬁcant clinical improvement on this diet (Lefevre
and Aronson, 2000). Similarly, alteration of energy metabolism by
supplementation with triheptanoin (Willis et al., 2010), had signif-
icant anti-convulsive effects in mice.
In light of the reduced ability to metabolize glucose, acetyl-L-
carnitine (ALCAR) may serve as an alternative energy source in
the brain and thus decrease seizure susceptibility. ALCAR is an
endogenous compound involved in the transport of acetyl-moie-
ties across the mitochondrial membrane. ALCAR readily crosses
the blood–brain barrier via the organic cation/carnitine trans-
porter OCTN2 (Kido et al., 2001; Parnetti et al., 1992) and carni-
tine transporters from the OCTN family are present on both
neurons and astrocytes (Januszewicz et al., 2010, 2009). Acute AL-
CAR administration increases phosphocreatine and decreases lac-
tate and inorganic phosphate levels in the rat brain (Aureli et al.,
1990). In the mouse brain, chronic supplementation with ALCAR
decreases glucose utilization and increases the amounts of high
energy phosphates (Smeland et al., in press). Moreover, the 13C
0197-0186/$ - see front matter  2012 Elsevier Ltd. All rights reserved.
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labeled acetyl moiety of ALCAR may be used in the labeling of
amino acids such as glutamate and GABA (Scaﬁdi et al., 2010).
Of special interest in regard to a potential anti-convulsant effect,
ALCAR protects against excitotoxicity in cell cultures (Forloni
et al., 1994). Additionally, ALCAR has been proposed to be prefer-
entially metabolized in GABAergic neurons in the rat brain (Scaﬁdi
et al., 2010).
Chemical rodent seizure models have played a vital role in gain-
ing understanding of the basic mechanisms of epileptogenesis, the
neurometabolic implications of seizures and antiepileptic treat-
ment. Pentylenetetrazole (PTZ) was ﬁrst described as a convulsant
in 1926 (Hildebrandt, 1926), and its biological and pharmacologi-
cal proﬁle has been thoroughly investigated (Loscher et al.,
1991). As chemoconvulsant, PTZ is used in different acute seizure
models (Eloqayli et al., 2003; Green and Murray, 1989; Nutt
et al., 1986), in the kindling model (Karler et al., 1989; Kondziella
et al., 2002, 2003; Mason and Cooper, 1972) and in models of
chronic convulsive seizures (Cremer et al., 2009). Given in appro-
priate dosage, PTZ is considered to be a model of generalized to-
nic-clonic seizures (Sarkisian, 2001). Kindling, the phenomenon
by which repeated injections of a subconvulsive dose leads to an
incremental increase in seizure response as a function of number
of injections, is commonly viewed as a model of epileptogenesis
and temporal lobe epilepsy (Bertram, 2007; Morimoto et al.,
2004). The mechanism of action of PTZ is only partly understood,
but an important mechanism is the binding to the picrotoxin-bind-
ing site on the GABA-A receptor (Ramanjaneyulu and Ticku, 1984;
Squires et al., 1984). Even though the main effect is believed to be a
reduction of GABAergic inhibition, PTZ affects several neurotrans-
mitter systems (Maciejak et al., 2010; Szyndler et al., 2010). In pre-
vious studies it has been shown that metabolic alterations happen
in cortex and hippocampus of animals subjected to one dose of PTZ
or to kindling (Carmody and Brennan, 2010; Eloqayli et al., 2003).
Eid et al. (2007) have shown that phosphate activated glutaminase
expression was increased in hippocampus of patients with chronic
MTLE and Petroff et al. (2002) showed reduced glutamate gluta-
mine cycling in the same area. Furthermore, cortex and the HF
are the brain regions which are most prone to primary neurohist-
opathologic change due to status epilepticus in humans and animal
models (Drislane, 2005). Therefore we chose to study metabolic
alterations in these areas in animals that had experienced repeated
generalized tonic-clonic convulsions. It should be stressed that
even though PTZ injection has been shown to cause changes in
neuronal architecture in the hippocampus (Cavazos et al., 2004)
it does not induce neuronal death (Planas et al., 1994; Valente
et al., 2004).
In this context we asked if ALCAR supplementation could affect
seizure activity and induce metabolic alterations in PTZ kindled
mice. In order to address the question we used [1-13C]glucose in
combination with 1H and 13C ex vivo nuclear magnetic resonance
spectroscopy (NMRS) and HPLC and determined regional brain en-
ergy metabolism, as well as the concentrations of dopamine, sero-
tonin and noradrenaline in the early postictal period in PTZ kindled
mice.
2. Materials and methods
2.1. Chemicals
[1-13C]glucose (99% 13C) and D2O (99.9%) were purchased from
Cambridge Isotope Laboratories (Woburn, MA, USA), ethylene gly-
col from Merck (Darmstad, Germany), and acetyl-L-carnitine (AL-
CAR), valproate and pentylenetetrazole (PTZ) from Sigma–Aldrich
(St. Louis, MO, USA). All other chemicals were of the purest grade
available from local commercial sources.
2.2. Animal model
The Norwegian National Animal Research Authority and the lo-
cal ethics committee approved the experimental procedures. Male
NMRI mice (n = 28; Taconic, Ejby, Denmark) were used in the
experiment. The mice had an average weight of 25 ± 0.7 g at the
start of the study. The animals were randomly separated into four
groups: (1) chronically saline injected mice (control mice), (2)
PTZ-kindled mice, (3) ALCAR-supplemented PTZ-kindled mice
(PTZ–ALCAR mice) and (4) valproate-treated PTZ-kindled mice
(PTZ–valproate mice). In the PTZ-kindled group one mouse died
from status epilepticus, and one was found moribund. One
mouse died in the PTZ–ALCAR group during status epilepticus.
All animals were maintained under standard laboratory conditions
on a 12/12-h light/dark cycle (lights on at 7AM), at a constant
temperature of 22 C and a humidity of 60%. Animals were housed
in individual cages with free access to food and water. The mice
were acclimatized to the above conditions for 1 week before the
start of the experiments.
The ALCAR groups received a 1.5 g/L solution of ALCAR as drink-
ing water (pH adjusted to 6), and were allowed to drink ad libitum.
PTZ-ALCAR mice drank approximately 10 ml per day (data not
shown), which would provide a daily ALCAR dose of approximately
500 mg/kg body weight. The PTZ–valproate group received a 3.3 g/
L solution of valproate in water (pH 7.5), and was allowed to drink
ad libitum. Valproate receiving mice typically drank approximately
8 ml per day (data not shown), which would provide a daily val-
proate dose of approximately 900 mg/kg body weight. The control
mice and PTZ-control mice typically drank 7.5 ml water per day.
ALCAR and valproate were supplemented in the drinking water
for 4 days before the experimental procedure with PTZ started.
At the end of the study, the mean weights of the groups were: con-
trol mice: 36.5 ± 0.7 g; PTZ-control mice: 34.2 ± 1.6 g; PTZ–ALCAR
mice: 35.7 ± 1.1 g; and PTZ–valproate mice: 32.1 ± 0.7 g. The
PTZ–valproate mice had a signiﬁcantly lower weight compared to
control mice and PTZ–ALCAR mice.
Mice were intraperitoneally injected with PTZ (43 mg/kg, PTZ-
kindled, PTZ–ALCAR and PTZ–valproate groups) or saline (0.1 mg/
kg, control group) three times a week for three weeks while they
received normal drinking water or water supplemented with AL-
CAR or valproate. After PTZ injection mice were observed for
30 min for latency to clonic convulsions and the severity of convul-
sions was scored according to a modiﬁed Racine scale (0 = no re-
sponse, 1 = 1–3 myoclonic jerks and/or facial twitching and/or
axial waves going though the body, 2 = more than three myoclonic
jerks, 3 = clonic convulsion with forelimb clonus without loss of
postural control, 4 = clonic convulsion with loss of postural control,
turning to the side and/or rearing, 5 = clonic convulsion with loss
of righting reﬂex and/or bouncing, two or more clonic convulsions,
tonic convulsion or status epilepticus). The mice were randomized
before PTZ injections, and the observers were blinded to the iden-
tity of the animal.
The mice received a ﬁnal dose of PTZ or saline and were, 15 min
later, intraperitoneally injected with [1-13C]glucose (543 mg/kg,
0.3 M solution). This protocol of glucose injection leads to blood
glucose levels well within the normoglycemic range
(8.2 ± 0.5 mmol/L; Hassel et al., 1995). 15 min after the glucose
injection, the mice were subjected to microwave ﬁxation at 4 kW
for 1.7 s (Model GA5013, Gerling Applied Engineering, Modesto,
CA, USA). The time interval of 15 min after glucose injection was
chosen based on our previous experiments (Hassel et al., 1995).
The brains were removed and the cortex and hippocampal forma-
tion (HF) were dissected and stored at 80 C till extraction. The
HF included the dentate gyrus, hippocampus proper, subiculum,
but not entorhinal cortex. The tissue samples were homogenized
in 0.7% perchloric acid using a Vibra Cell sonicator (Model VCX
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750, Sonics & Materials, Newtown, CT, USA). Thereafter the sam-
ples were centrifuged at 4400 g and 4 C for 5 min. The procedure
was repeated, the supernatants were pooled and samples for
monoamine HPLC analysis were removed. Thereafter, pH was ad-
justed to 6.5–7.5 with 1 M KOH followed by centrifugation and
lyophilization.
2.3. High performance liquid chromatography (HPLC)
To determine the total amount of glutathione (reduced plus oxi-
dized) the samples were analyzed using a Hewlett Packard 1100
System (Agilent Technologies, Palo Alto, CA, USA) with ﬂuores-
cence detection, after derivatization with o-phtaldialdehyde (Ged-
des and Wood, 1984). The components were separated with a
ZORBAX SB-C18 (4.6  150 mm, 3.55 lm) column from Agilent
using 50 mM sodium phosphate buffer (pH 5.9) with 2.5% tetrahy-
drofurane and methanol (98.75%) with tetrahydrofurane (1.25%) as
eluents. The amount of glutathione was quantiﬁed by comparison
with a standard curve derived from a standard solution of glutathi-
one run repeatedly with 15 samples intervals.
To determine the amounts of monoamines, the samples were
analyzed using an Agilent 1200 system (Agilent, USA) with an elec-
trochemical detector (Coulochem III, ESA, Sunnyvale, CA, USA). The
components were separated with an Eclips XDB-C18 column
(4.6  150 mm, 5 lm, Agilent) with an aqueous mobile phase
(0.90 mL/min) containing 90 mM NaH2PO4, 50 mM citric acid,
0.1 mM EDTA, 0.5 mM octanesulfonic acid and 7% methanol solu-
tion. The amounts of monoamines were quantiﬁed by comparison
with a standard curve derived from standard solutions of monoam-
ines run after every 15th sample.
2.4. 13C and 1H nuclear magnetic resonance (NMR) spectroscopy
Lyophilized samples were dissolved in 200 lL of D2O containing
0.01% ethylene glycol as an internal standard for quantiﬁcation. pH
was re-adjusted to 6.5–7.5, and samples were transferred into
5 mm Shigemi NMR microtubes (Shigemi Inc., Allison Park, PA,
USA).
The HF samples were analyzed using a BRUKER DRX-600 spec-
trometer (BRUKER Analytik GmbH, Rheinstetten, Germany), while
the cortex samples were analyzed using a BRUKER DRX-500 spec-
trometer. The spectra were recorded at 25 C. 1H NMR spectra were
acquired on the same instruments with the following parameters:
pulse angle of 90, acquisition time 1.36 s and relaxation delay
10 s. The number of scans was 128 and 1024 for cortical and hip-
pocampal extracts, respectively. Water suppression was achieved
by applying a low-power pre-saturation pulse at the water fre-
quency. Proton decoupled 13C NMR spectra were obtained using
a 30 pulse angle and 30 kHz spectral width with 64 K data points
employing an acquisition time of 1.08 s and a relaxation delay of
0.5 s. The number of scans needed to obtain an appropriate signal
to noise ratio was typically 25,000 for the cortex samples and
35,000 for the HF samples.
Relevant peaks in the spectra were identiﬁed and integrated
using XWINNMR software (BRUKER BioSpin GmbH, Rheinstetten,
Germany). The total amounts and 13C labeling of metabolites were
Fig. 1. Typical 13C NMR spectrum from cerebral cortex extract of a PTZ–ALCAR mouse. Peak assignment: 1:b-glucose C-1; 2: a-glucose C-1; 3: aspartate C-3; 4: GABA C-2; 5:
glutamate C-4; 6: glutamine C-4; 7: lactate C-3; 8: alanine C-3.
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quantiﬁed from the integrals of the peak areas using ethylene gly-
col as an internal standard. Correction for natural abundance, nu-
clear Overhauser enhancement and relaxation effects relative to
the internal standard were applied to all relevant resonances.
2.5. Labeling patterns of compounds from metabolism of
[1-13C]glucose
Fig. 1 shows a typical 13C NMR spectrum. To interpret the 13C
incorporation results it is necessary to analyze the metabolism of
[1-13C]glucose (Fig. 2). via glycolysis, [1-13C]glucose is converted
to [3-13C]pyruvate, which can be further converted to [3-13C]ala-
nine, [3-13C]lactate or [2-13C]acetyl-CoA. [2-13C]acetyl-CoA may
enter the tricarboxylic acid (TCA) cycle through condensation with
oxaloacetate to form [4-13C]citrate. Eventually the TCA cycle inter-
mediate [4-13C]a-ketoglutarate is formed, which is the precursor
of [4-13C]glutamate. Thereafter, [4-13C]glutamate may be trans-
formed to [4-13C]glutamine in astrocytes due to the astrocyte spe-
ciﬁc localization of glutamine synthetase (Norenberg and
Martinez-Hernandez, 1979) and to [2-13C]GABA in GABAergic neu-
rons. If [4-13C]a-ketoglutarate is further converted in the TCA cy-
cle, labeled oxaloacetate will be formed which can be
transaminated to [2-13C]aspartate or [3-13C]aspartate. Further cy-
cling of labeled metabolites give rise to different labeling patterns
in amino acids (Alvestad et al., 2008).
2.6. Data analysis
Statistical analysis of metabolites and seizure latency was per-
formed using one-way ANOVA followed by a least signiﬁcant dif-
ference post hoc test, were p < 0.05 was regarded as signiﬁcant.
Analysis of seizure severity was performed using a Kruskal–Wallis
test (nonparametric ANOVA) followed by a Mann–Whitney U test.
All data are represented as mean ± S. Due to technical problems,
the number of analyses varied between analytical methods.
3. Results
The objective of the present study was to investigate possible
beneﬁcial effects of ALCAR in a PTZ kindling model. The progres-
sion of kindling is presented in Fig. 3A. Valproate delayed the pro-
gression of kindling in the initial stage of the experiment evidenced
by a signiﬁcantly lower Racine score on injection day 3. However,
valproate did not delay the occurrence of full kindling. PTZ–ALCAR
mice had the same kindling progression as PTZ kindled mice. La-
tency to clonic convulsions was not affected by valproate or ALCAR
(Fig. 3B).
Microwave ﬁxation was performed on injection day 10, thus all
metabolic analyses were at a time point when seizures were at a
maximum and there were no differences in Racine score between
groups. This provided an opportunity to assess ALCAR’s metabolic
effects on animals subjected to repeated generalized tonic-clonic
convulsions. In the HF, four groups were compared: (1) control
mice, (2) PTZ-kindled mice, (3) PTZ–ALCAR mice and (4) PTZ–val-
proate mice. In cortex, three groups were compared: (1) control
mice, (2) PTZ-kindled mice and (3) PTZ–ALCAR mice.
Analyses of 1H NMR spectra from cerebral cortex and HF en-
abled us to quantify many metabolites. Total amount of glucose,
lactate and alanine are presented in Table 1. Together with acet-
yl-CoA, both lactate and alanine are derived from the end-product
of glycolysis, pyruvate. In cortex, total amount of glucose was in-
creased in all PTZ-kindled animals compared to control, whereas
Fig. 2. Schematic representation of isotopomers derived from [1-13C]glucose. Black circles indicate 13C labeling. Only the ﬁrst turn of the TCA cycle is illustrated.
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Fig. 3. Development of kindling in pentylenetetrazole (PTZ)-kindled mice, PTZ-kindled mice supplemented with acetyl-L-carnitine (ALCAR), and PTZ-kindled mice treated
with valproate. Mice were i.p. injected with 43 mg/kg PTZ three times a week for three weeks. (A) Severity of seizures as a function of injections. (B) Latency (in seconds) to
ﬁrst clonic convulsion. Analysis of seizure severity was performed using a Kruskal–Wallis test followed by a Mann–Whitney U test. Latency was analyzed using a one-way
ANOVA followed by a LSD post hoc test. Data are represented as mean ± SEM, and the superscripts (a, b) indicate a statistically signiﬁcant difference to the PTZ-group and the
PTZ–ALCAR group respectively (p < 0.05).
Table 1
Amounts, 13C-labeling and percent 13C enrichment of glucose, lactate and alanine in brain extracts of hippocampal formation and cortex from control mice, PTZ-kindled mice,
PTZ–ALCAR treated mice, and PTZ–valproate treated mice.
nmol/g tissue Hippocampal formation Cortex
ControlA n = 5 PTZ n = 5 PTZ-ALCAR n = 5 PTZ-valproate n = 6 Control n = 5 PTZ n = 5 PTZ–ALCAR n = 4
Glucose 2410.1 ± 315.1 3053.3 ± 174.1 3248.3 ± 354.0 3785.2 ± 298.8a 3042.1 ± 247.6 5205.8 ± 317.6a 4948.2 ± 235.0a
[1-13C]glucose 601.0 ± 79.0 702.0 ± 49.7 649.0 ± 31.4 789.2 ± 42.1 553.4 ± 33.4 687.0 ± 94.3 606.0 ± 23.2
13C enrichment glucose 25.9 ± 3.7 23.2 ± 1.8 20.9 ± 2.4 21.1 ± 1.4 18.6 ± 1.5 13.2 ± 1.7a 12.3 ± 0.8a
Lactate 4999.9 ± 1280.1 2167.2 ± 163.0a 3309.3 ± 530.6 2804.1 ± 137.3a 4548.2 ± 570.4 2992.1 ± 329.4 3596.5 ± 552.6
[3-13C]lactate 320.2 ± 120.0 60.2 ± 9.2a 121.0 ± 15.1a 86.1 ± 18.4a 170.1 ± 34.4 85.5 ± 12.5a 82.7 ± 21.2a
13C enrichment lactate 5.9 ± .10 2.8 ± 0.5 4.3 ± 1.0 3.0 ± 0.6 3.7 ± 0.5 3.0 ± 0.6 2.2 ± 0.3
Alanine 1004.0 ± 50.5 742.4 ± 54.2 909.1 ± 140.2 809.9 ± 134.6 1042.7 ± 84.8 1130.4 ± 204.2 1192.5 ± 119.3
[3-13C]alanine 68.7 ± 13.3 24.2 ± 1.5a 57.9 ± 8.3b 37.9 ± 12.7 53.6 ± 9.4 36.2 ± 1.3 33.2 ± 6.0
13C enrichment alanine 6.8 ± 1.3 3.4 ± 0.4 6.5 ± 0.8 4.0 ± 1.3 5.0 ± 0.5 3.7 ± 0.8 2.9 ± 0.3
Amounts of metabolites were calculated using data from 1H- and 13C-NMRS. See Materials and methods for details. Data represent mean ± SEM, and the superscripts (a,b)
indicate a statistically signiﬁcant difference to the control group, the PTZ group and the PTZ–ALCAR group respectively (p < 0.05).
A For the glucose data the control group included only four mice. Control data from Smeland et al. (epub).
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only PTZ–valproate mice had a signiﬁcant increase in the HF. Lac-
tate levels in the HF of PTZ-kindled mice and PTZ–valproate mice
were signiﬁcantly decreased, which can indicate reduced glycolytic
activity. Amounts of alanine were unaltered in both brain regions.
[1-13C]glucose was administered 15 min. before microwave ﬁx-
ation and the labeling from glucose and glycolysis products was
determined by 13C NMRS. Table 1 presents levels of [1-13C]glucose,
[3-13C]lactate and [3-13C]alanine. The amount of [1-13C]glucose
was unaltered in both brain areas in all groups. [3-13C]lactate con-
tent was decreased in both brain regions in all PTZ-kindled ani-
mals. [3-13C]alanine content was unaltered in cortex, but was
signiﬁcantly decreased in PTZ kindled mice in the HF. Interestingly,
the amount was signiﬁcantly higher in PTZ–ALCAR mice compared
to PTZ kindled mice.
PTZ–valproate mice had a signiﬁcantly lower weight at the end
of the experiment. This weight difference did not affect glucose
availability, since glucose was administered according to weight.
Furthermore, glucose enrichment was similar in HF in all mice.
In Table 2 we list metabolites related to energy status: AMP + AD-
P + ATP (adenosine monophosphate + adenosine diphos-
phate + adenosine triphosphate), creatine, phosphocreatine and
NADH; the TCA cycle intermediate succinate; the osmolytes tau-
rine and myo-inositol; choline containing compounds; N-acetyl
aspartate (NAA) and the antioxidant glutathione (the sum of the
reduced and oxidized forms). In the cortex of PTZ-kindled mice to-
tal amount of succinate was signiﬁcantly decreased, whereas that
of myo-inositol was signiﬁcantly elevated. In the HF, valproate
treatment increased the glutathione level, whereas the levels of
choline containing compounds were signiﬁcantly decreased in
PTZ-kindled mice and in PTZ–ALCAR mice. The amount of the
monoamines dopamine, noradrenaline and serotonin are also pre-
sented in Table 2. Dopamine concentration was increased in HF of
PTZ-kindled and PTZ–valproate mice compared to control.
The amino acids essential for glutamatergic and GABAergic neu-
rotransmission: glutamate, glutamine, GABA and aspartate are pre-
sented in Fig. 4 (cortex) and Fig. 5 (HF). In cortex, total amounts of
glutamate, glutamine, GABA and aspartate were not altered. How-
ever, labeling from [1-13C]glucose in [4-13C]glutamate, [4-13C]glu-
tamine, [2-13C]GABA and [3-13C]aspartate was signiﬁcantly
decreased in PTZ and PTZ–ALCAR groups compared to control. Per-
cent enrichment in glutamate, glutamine and aspartate was simi-
larly decreased. In the PTZ kindled mice, percent enrichment in
GABA was decreased compared to control, whereas in PTZ–ALCAR
mice, percent enrichment in GABA was decreased compared to
control and PTZ kindled mice. GABA content was similar between
PTZ and PTZ–ALCAR mice, whereas in [2-13C]GABA content there
was a reduction of 32% (p = 0.08) between the two groups. In HF,
total amount of glutamate was decreased in all PTZ-kindled ani-
mals. Percent 13C enrichment was unaltered, whereas [4-13C]gluta-
mate and [2-13C]GABA content was decreased in all PTZ-kindled
animals.
4. Discussion
We investigated the antiseizure capability and metabolic effects
of ALCAR on mice subjected to PTZ kindling using a similar exper-
imental protocol of PTZ injection as Hansen et al. (2009). This
group demonstrated that ketogenic diet was able to delay kindling
development. We compared the effects of the dietary supplement
ALCAR to those of the well-established antiepileptic drug valpro-
ate, which has been shown to delay kindling (Abdallah, 2010). In
the present study, valproate did delay the progression of kindling
slightly in the initial phase, but, in agreement with Ohno et al.
(2010) did not delay the occurrence of full kindling. To our disap-
pointment the PTZ–ALCAR mice showed the same kindling pro-
gression and latency to clonic convulsions as those that received
PTZ alone.
PTZ-kindling affected glucose metabolism in the present study
in agreement with earlier reports on postictal hypometabolism
(Cooper et al., 2001; Hagemann et al., 1998). Valproate reduces
TCA turnover in mice (Johannessen et al., 2001) and, in concur-
rence, global CMRglc in epilepsy patients and healthy volunteers
receiving valproate is decreased (Gaillard et al., 1996; Leiderman
et al., 1991). In addition ALCAR has been shown to decrease glucose
metabolism (Smeland et al., in press).
4.1. The effect of PTZ kindling on glucose metabolism
Increased glucose content was detected in cortex of all PTZ kin-
dled mice, indicating reduced glucose utilization (Lei et al., 2010).
In the HF, decreased glucose utilization was only statistically sig-
niﬁcant in PTZ–valproate mice. However, the reduction in lactate
concentration and amount of [3-13C]lactate in PTZ-kindled mice to-
gether with the reduction of [3-13C]alanine content, did point to
hippocampal glucose hypometabolism in the PTZ-kindled mice.
Table 2
Amounts (lmol/g tissue) of metabolites in brain extracts of hippocampal formation and cortex from control, PTZ-kindled, PTZ–valproate and PTZ–ALCAR mice.
Hippocampal formation Cortex
Control n = 5 PTZ n = 5 PTZ-ALCAR n = 6 PTZ-valproate n = 5 Control n = 5 PTZ n = 5 PTZ-ALCAR n = 5
AMP + ADP + ATP 1.6 ± 0.4 1.8 ± 0.2 1.4 ± 0.3 1.7 ± 0.3 2.5 ± 0.2 2.6 ± 0.3 2.4 ± 0.3
Creatine 8.6 ± 0.4 7.5 ± 0.7 8.4 ± 0.4 7.8 ± 0.6 9.6 ± 0.9 9.2 ± 0.6 9.4 ± 0.4
Phosphocreatine 1.6 ± 0.5 2.2 ± 0.4 1.1 ± 0.2 1.9 ± 0.4 1.1 ± 0.3 1.4 ± 0.2 1.1 ± 0.2
NADH n.q n.q n.q n.q 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0
NAA 4.6 ± 0.5 3.7 ± 0.3 3.7 ± 0.2 4.1 ± 0.4 8.9 ± 0.7 8.9 ± 0.5 9.2 ± 0.6
Succinate 0.5 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 0.9 ± 0.3 0.4 ± 0.2 0.2 ± 0.0a 0.3 ± 0.1
Taurine 11.1 ± 0.6 10.3 ± 0.5 10.5 ± 0.6 10.7 ± 0.4 13.4 ± 1.0 12.0 ± 1.0 13.9 ± 0.9
Glutathione 1.3 ± 0.1 1.3 ± 0.1 1.2 ± 0.1 1.9 ± 0.1abc 1.2 ± 0.1 1.3 ± 0.0 1.3 ± 0.1
Myo-inositolA 10.1 ± 1.0 11.3 ± 0.6 9.2 ± 1.3 10.8 ± 1.0 5.9 ± 0.4 8.3 ± 0.9a 7.7 ± 0.1
Choline containing compounds 1.7 ± 0.0 1.3 ± 0.2a 1.3 ± 0.0a 1.5 ± 0.1 1.8 ± 0.1 1.6 ± 0.1 1.6 ± 0.1
Dopamine 0.2 ± 0.1 0.7 ± 0.1a 0.5 ± 0.1 0.8 ± 0.1ac 3.8 ± 0.9 5.4 ± 0.7 3.3 ± 0.5
Noradrenaline 1.9 ± 0.1 1.6 ± 0.1 1.6 ± 0.2 1.6 ± 0.2 1.7 ± 0.1 1.6 ± 0.1 1.5 ± 0.1
Serotonin 3.8 ± 0.5 4.5 ± 0.2 3.8 ± 0.3 4.5 ± 0.4 3.0 ± 0.2 3.7 ± 0.2 3.4 ± 0.4
Mice received ALCAR or valproate in the drinking water for 25 days, and two groups were injected with PTZ intraperitoneally three times a week (for details see Materials and
methods). All metabolites were obtained using 1H NMRS, with the exception for glutathione, which was measured by HPLC, and Myo-inositol, which was measured by 13C
NMRS.
Abbreviations: n.q: not quantiﬁable; NAA: N-acetyl aspartate. Data represent mean ± SEM, and the superscripts (a, b, c) indicate a statistically signiﬁcant difference to the
control group, the ALCAR group and the PTZ group, respectively (p < 0.05). Control data from Smeland et al. (epub).
A The PTZ–ALCAR group included only ﬁve mice for the hippocampal formation, and four mice for the cortex.
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Using an experimental protocol similar to ours, Yudkoff et al.
(2003) concluded that glucose metabolism was enhanced as a con-
sequence of a seizure-induced energy deﬁcit. The discrepancy be-
tween the hypometabolism detected by us and the
hypermetabolism reported by Yudkoff et al. (2003) may be due
to differences in interpretation and the fact that we analyzed the
entire cortex cerebri whereas Yudkoff et al. (2003) analyzed the
forebrain. Alterations in the rate of glucose metabolism have also
been assessed in cell culture studies of astrocytes, where glycolysis
was decreased by short-term incubation with PTZ, whereas long-
term incubation caused increased glycolysis (Qu et al., 2005). The
present data do not allow a conclusive statement regarding in
which compartment(s) glycolysis is altered.
Not only glycolysis but also TCA cycle activity was affected in
the PTZ-kindled mice. Pyruvate, the end point of glycolysis, is the
precursor for lactate, alanine and acetyl-CoA. In cortex in the pres-
ent study, 13C enrichment in glucose was decreased but that of lac-
tate and alanine was unchanged and thus it is likely that also 13C
enrichment in acetyl-CoA was unchanged. Taken together with a
decrease in succinate level, the reduction in 13C enrichment and
amount of [4-13C]glutamate, [2-13C]GABA, [4-13C]glutamine and
[3-13C]aspartate suggests a reduced TCA cycle turnover in the early
post-ictal phase in glutamatergic and GABAergic neurons. In HF 13C
enrichment in glucose was not altered. The amounts of [4-13C]glu-
tamate and [2-13C]GABA were decreased together with a decrease
in the amount of glutamate indicating involvement of both gluta-
matergic and GABAergic neurons. The observed decreased TCA cy-
cle turnover is in agreement with results from a study using
cultured cerebellar granule neurons, where reduced TCA cycle
turnover was detected (Eloqayli et al., 2002). Also after a single
injection of PTZ, TCA-cycle activity was reduced, though mostly
in glutamatergic neurons, not in astrocytes (Eloqayli et al., 2003).
Glial involvement has been shown in PTZ-kindling experiments
using senescent-accelerated mice (Kondziella et al., 2003). The in-
crease in myo-inositol in cortex in the present study points to-
wards glial involvement since most myo-inositol is localized in
Fig. 4. Amounts and labeling of glutamate, glutamine, GABA and aspartate in the cortex of control mice (n = 5, black bars), PTZ-kindled mice (n = 5, striped bars), and PTZ–
ALCAR treated mice (n = 4, white bars). (A) The amounts of metabolites (lmol/g tissue) were obtained by 1H NMRS. (B) The amounts of 13C-labeled metabolites (nmol/g
tissue) were obtained by 13C NMRS. (C) The percent 13C-enrichments of amino acids were calculated using data from 1H- and 13C-NMRS. The results are expressed as
mean ± SEM, and the superscripts (a, b) indicate a statistically signiﬁcant difference to the control group and the PTZ-group respectively (p < 0.05). Control data from Smeland
et al. (in press).
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astrocytes (Brand et al., 1993; Meisingset et al., 2010). However,
even though the reduction in [4-13C]glutamine labeling may sug-
gest astrocytic involvement in cortex, this reduction could also
be due to a disturbance in neuronal release of [4-13C]glutamate.
The latter explanation is supported by the unaltered total amount
of glutamine in both HF and cortex. Indeed, in HF, unaltered
[4-13C]glutamine labeling indicates unaffected mitochondrial
metabolism in astrocytes.
Amounts of the neurotransmitters glutamate, GABA and aspar-
tate were not altered in the present study, except for a reduction in
glutamate in HF. Similarly, Maciejak et al. (2010) demonstrated a
down regulation of glutamate levels in the hippocampus after
administration of a single dose of PTZ, but this effect was not seen
after kindling. These authors have shown that homeostasis of
excitatory and inhibitory amino acids during the PTZ kindling pro-
cess is complex, with great variations between brain regions. De-
crease of glutamate concentration is also seen in the kainate and
lithium-pilocarpine models of temporal lobe epilepsy (Alvestad
et al., 2008; Melo et al., 2005), indicating that the observed down
regulation of glutamate content is not PTZ speciﬁc, but possibly
due to seizures.
4.2. The effects of ALCAR on glucose metabolism in PTZ kindling
It is well established that the uptake of ALCAR into brain tissue
is efﬁcient (Kuratsune et al., 1997; Scaﬁdi et al., 2010). Since OCTN
transporters are found on both astrocytes and neurons, ALCAR may
be internalized in both compartments. Moreover, chronic ALCAR
supplementation does not alter the blood glucose level (Freo
et al., 2009; Ori et al., 2002). Thus, the PTZ–ALCAR mice had the
same glucose availability as the other PTZ kindled mice.
In the HF, PTZ kindling reduced the amounts of lactate and
[3-13C]alanine compared to control mice. Interestingly, ALCAR sup-
plementation normalized these PTZ induced alterations, indicating
a positive effect of ALCAR on glucose metabolism in this region.
Importantly, since PTZ-kindled mice and PTZ–ALCAR mice had a
Fig. 5. Amounts and labeling of glutamate, glutamine, GABA and aspartate in the hippocampal formation of control mice (n = 5, black bars), PTZ-kindled mice (n = 5, striped
bars), PTZ–ALCAR treated mice (n = 5, white bars), and PTZ–valproate treated mice (n = 6, gray bars). A: The amounts of metabolites (lmol/g tissue) were obtained by 1H
NMRS. (B) The amounts of 13C-labeled metabolites (nmol/g tissue) were obtained by 13C NMRS. (C) The percent 13C-enrichments of amino acids were calculated using data
from 1H- and 13C-NMRS. The results are expressed as mean ± SEM, and the superscripts (a, b, c) indicate a statistically signiﬁcant difference to the control group, the PTZ group
and the PTZ–ALCAR group respectively (p < 0.05). Control data from Smeland et al. (in press).
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similar kindling development, such differences are a result of AL-
CAR speciﬁc effects on metabolism and not a consequence of dif-
ferences in seizure activity.
Catabolism of ALCAR can lead to mitochondrial acetyl-CoA for-
mation which could dilute the amount of [1-13C]glucose derived
[2-13C]acetyl-CoA in our study. The fact that the amount of
[3-13C]alanine was normalized in PTZ–ALCAR mice compared to
PTZ-kindled mice can be interpreted as a partial redirection of
pyruvate because the TCA cycle is also supplied with the acetyl
moiety of ALCAR. However, we have previously shown that only
the conversion of glucose into lactate, i.e. anaerobic glycolysis, is
affected by the presence of ALCAR while the conversion of glucose
into pyruvate which via acetyl CoA subsequently enters the TCA
cycle is not affected by ALCAR (Smeland et al., in press). Indeed,
also in the present study, the PTZ–ALCAR mice showed the same
reduction in 13C label in glutamate, glutamine, GABA and aspartate
as PTZ-kindled mice. However, 13C enrichment of GABA in cortex of
PTZ–ALCAR mice was lower compared to that of PTZ-kindled mice.
No alterations were detected in GABA levels in PTZ–ALCAR mice,
even though ALCAR has been shown to induce a decrease in the
GABA concentration in HF of healthy mice (Smeland et al., in
press). In light of the unaltered GABA content the reduction in
13C enrichment may suggest incorporation of the unlabeled acet-
yl-moiety of ALCAR into GABA, which then would dilute 13C-label
from [1-13C]glucose incorporation. This is in compliance with the
results of Scaﬁdi et al. (2010) which demonstrated increased 13C
enrichment of GABA after [2-13C]ALCAR supplementation. As the
authors discussed, this high 13C enrichment of GABA could indicate
a preferential metabolism of ALCAR in GABAergic neurons. Fur-
thermore, ALCAR did not alter the PTZ-induced reduction in gluta-
mate content in the HF. ALCAR failed to reverse the major PTZ
effects on TCA cycle metabolites.
In a previous study, ALCAR has shown the capability to increase
amounts of phosphocreatine and adenosine phosphates (Smeland
et al., in press). In the present study, however, the concentrations
of high-energy phosphates were similar in PTZ–ALCAR mice com-
pared to PTZ-kindled mice and control mice. In cortex ALCAR also
had a normalizing effect on the level of myo-inositol, suggesting a
reduced PTZ inﬂuence on astrocytes.
4.3. Comparison of the metabolic effects of ALCAR and valproate
PTZ induced many metabolic alterations which were not com-
pensated for by either ALCAR or valproate. The latter did, however,
increase the amount of glutathione. A major metabolic effect of
valproate is potentiation of GABAerigc metabolism (Loscher,
1981, 1999, 2002) and ALCAR may be preferentially metabolized
in GABAerig neurons (Scaﬁdi et al., 2010). PTZ, on the other hand,
diminishes GABAergic inhibition through binding to the GABA-A
receptor. In spite of these similarities, the metabolic changes
caused by valproate were not paralleled by the changes induced
by ALCAR supplementation.
4.4. The effects of ALCAR and valproate on monoamine metabolism in
PTZ kindling
It has been shown that monoamine neurotransmission and
metabolism is of importance in seizure control in a number of ani-
mal models including the PTZ kindling model (Szyndler et al.,
2010). There are many studies supporting the hypothesis that
dopamine exerts an antiepileptic effect in man and animal models
(Starr, 1996). In dopamine D2 receptor knock-out mice, systemic
administration of the glutamatergic agonist kainic acid caused sub-
stantial hippocampal cell death compared to wild type (Bozzi et al.,
2000). The results suggest a neuroprotective role of dopamine
against excitotoxicity. Interestingly, dopamine concentration was
increased in the HF of PTZ-kindled mice in the present study. This
is in agreement with results reported from the HF of rat pups (age
P10, P14, P17, P21) subjected to 60 min of PTZ induced status epi-
lepticus (el Hamdi et al., 1992). However, Szyndler et al. (2010) did
not obtain an increase in dopamine concentration in hippocampus
of PTZ-kindled animals compared to chronic saline-injected ani-
mals. But there was a signiﬁcant increase in dopamine in PTZ-kin-
dled animals compared to single saline-injected animals. These
ﬁndings suggest that dopamine alterations may be a result of stress
caused by chronic injections per se. However, in our study, all ani-
mals had the same number of i.p. injections.
Supplementation with ALCAR attenuated the increase in dopa-
mine in HF in PTZ-kindled mice. The fact that PTZ-kindled mice
had a signiﬁcantly higher level of dopamine compared to control
mice, but PTZ–ALCAR mice did not, may indicate that ALCAR de-
prived the brain of a protective measure. However, the same result
may indicate that ALCAR prevented the underlying cause of dopa-
mine increase, possibly hippocampal cell death. Even though NAA
was not reduced, such a measurement may not be sensitive en-
ough to detect small alterations in subpopulations of hippocampal
neurons. Previously, we have shown that ALCAR supplementation
in healthy mice increased noradrenaline content in the HF and that
of serotonin in the cortex compared to animals receiving saline
injections, but no effects on dopamine were found (Smeland
et al., in press). Interestingly, the present data demonstrate that
ALCAR did not increase the amounts of serotonin and noradrena-
line, but did affect dopamine levels in PTZ kindled animals. This
indicates that ALCAR has different effects on monoamine levels
in healthy control mice compared to those in PTZ subjected mice.
5. Conclusion
ALCAR was able to attenuate the PTZ-induced reduction in 13C
labeled alanine in the hippocampal formation. It also modiﬁed
the dopamine increase in the HF. Thus, even though ALCAR did
not delay the kindling process, chronic supplementation did nor-
malize some metabolic alterations in the PTZ-kindled brain. How-
ever, it remains unanswered if these alterations could improve
current epilepsy treatment. The fact that valproate failed to prop-
erly reduce kindling development in the present study, argues that
ALCARmay have antiepileptic effects that the present investigation
failed to demonstrate. In light of our ﬁndings, the possibility of AL-
CAR as a supplement to current antiepileptic treatment is worthy
of further investigation.
Conﬂict of interests
The authors declare no conﬂict of interest.
Acknowledgments
The excellent technical assistance of Lars Evje is gratefully
appreciated. The authors wish to thank Elvar M. Eyjolfsson, Sivert
H. Sandvik and Mats L. Skillingstad for their help with the
experiments.
References
Abdallah, D.M., 2010. Anticonvulsant potential of the peroxisome proliferator-
activated receptor gamma agonist pioglitazone in pentylenetetrazole-induced
acute seizures and kindling in mice. Brain Res. 1351, 246–253.
Alvestad, S., Hammer, J., Eyjolfsson, E., Qu, H., Ottersen, O.P., Sonnewald, U., 2008.
Limbic structures show altered glial-neuronal metabolism in the chronic phase
of kainate induced epilepsy. Neurochem. Res. 33, 257–266.
Aureli, T., Miccheli, A., Ricciolini, R., Di Cocco, M.E., Ramacci, M.T., Angelucci, L.,
Ghirardi, O., Conti, F., 1990. Aging brain: effect of acetyl-L-carnitine treatment
on rat brain energy and phospholipid metabolism. A study by 31P and 1H NMR
spectroscopy. Brain Res. 526, 108–112.
452 O.B. Smeland et al. / Neurochemistry International 61 (2012) 444–454
Bell, G.S., Sander, J.W., 2001. The epidemiology of epilepsy: the size of the problem.
Seizure 10, 306–314; quiz 315–306.
Berg, A.T., 2008. Risk of recurrence after a ﬁrst unprovoked seizure. Epilepsia 49
(Suppl 1), 13–18.
Bertram, E., 2007. The relevance of kindling for human epilepsy. Epilepsia 48 (Suppl
2), 65–74.
Bozzi, Y., Vallone, D., Borrelli, E., 2000. Neuroprotective role of dopamine against
hippocampal cell death. J. Neurosci. 20, 8643–8649.
Brand, A., Richter-Landsberg, C., Leibfritz, D., 1993. Multinuclear NMR studies on the
energy metabolism of glial and neuronal cells. Dev. Neurosci. 15, 289–298.
Carmody, S., Brennan, L., 2010. Effects of pentylenetetrazole-induced seizures on
metabolomic proﬁles of rat brain. Neurochem. Int. 56, 340–344.
Cavazos, J.E., Jones, S.M., Cross, D.J., 2004. Sprouting and synaptic reorganization in
the subiculum and CA1 region of the hippocampus in acute and chronic models
of partial-onset epilepsy. Neuroscience 126, 677–688.
Cooper, R.M., Legare, C.E., Campbell Teskey, G., 2001. Changes in (14)C-labeled 2-
deoxyglucose brain uptake from nickel-induced epileptic activity. Brain Res.
923, 71–81.
Cremer, C.M., Palomero-Gallagher, N., Bidmon, H.J., Schleicher, A., Speckmann, E.J.,
Zilles, K., 2009. Pentylenetetrazole-induced seizures affect binding site densities
for GABA, glutamate and adenosine receptors in the rat brain. Neuroscience
163, 490–499.
Drislane, F., 2005. Status epilepticus: a clinical perspective. Humana Press, Totowa,
N.J.
Eid, T., Hammer, J., Runden-Pran, E., Roberg, B., Thomas, M.J., Osen, K., Davanger, S.,
Laake, P., Torgner, I.A., Lee, T.S., Kim, J.H., Spencer, D.D., Ottersen, O.P., de
Lanerolle, N.C., 2007. Increased expression of phosphate-activated glutaminase
in hippocampal neurons in human mesial temporal lobe epilepsy. Acta
Neuropathol. 113, 137–152.
el Hamdi, G., Boutroy, M.J., Nehlig, A., 1992. Effects of pentylenetetrazol-induced
seizures on dopamine and norepinephrine levels and on glucose utilization
in various brain regions of the developing rat. Int. J. Dev. Neurosci. 10,
301–311.
Eloqayli, H., Qu, H., Unsgard, G., Sletvold, O., Hadidi, H., Sonnewald, U., 2002. Effects
of pentylenetetrazole and glutamate on metabolism of [U-(13)C]glucose in
cultured cerebellar granule neurons. Neurochem. Int. 40, 181–187.
Eloqayli, H., Dahl, C.B., Gotestam, K.G., Unsgard, G., Hadidi, H., Sonnewald, U., 2003.
Pentylenetetrazole decreases metabolic glutamate turnover in rat brain. J.
Neurochem. 85, 1200–1207.
Fisher, R.S., van Emde Boas, W., Blume, W., Elger, C., Genton, P., Lee, P., Engel Jr., J.,
2005. Epileptic seizures and epilepsy: deﬁnitions proposed by the International
League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE).
Epilepsia 46, 470–472.
Forloni, G., Angeretti, N., Smiroldo, S., 1994. Neuroprotective activity of acetyl-L-
carnitine: studies in vitro. J. Neurosci. Res. 37, 92–96.
Freo, U., Dam, M., Ori, C., 2009. Cerebral metabolic effects of acetyl-L-carnitine in
rats during aging. Brain Res. 1259, 32–39.
Gaillard, W.D., Zefﬁro, T., Fazilat, S., DeCarli, C., Theodore, W.H., 1996. Effect of
valproate on cerebral metabolism and blood ﬂow: an 18F–2-deoxyglucose and
15O water positron emission tomography study. Epilepsia 37, 515–521.
Geddes, J.W., Wood, J.D., 1984. Changes in the amino acid content of nerve endings
(synaptosomes) induced by drugs that alter the metabolism of glutamate and
gamma-aminobutyric acid. J. Neurochem. 42, 16–24.
Green, A.R., Murray, T.K., 1989. A simple intravenous infusion method in rodents for
determining the potency of anticonvulsants acting through GABAergic
mechanisms. J. Pharm. Pharmacol. 41, 879–880.
Hagemann, G., Bruehl, C., Lutzenburg, M., Witte, O.W., 1998. Brain hypometabolism
in a model of chronic focal epilepsy in rat neocortex. Epilepsia 39, 339–346.
Hansen, S.L., Nielsen, A.H., Knudsen, K.E., Artmann, A., Petersen, G., Kristiansen, U.,
Hansen, S.H., Hansen, H.S., 2009. Ketogenic diet is antiepileptogenic in
pentylenetetrazole kindled mice and decrease levels of N-acylethanolamines
in hippocampus. Neurochem. Int. 54, 199–204.
Hassel, B., Sonnewald, U., Fonnum, F., 1995. Glial-neuronal interactions as studied
by cerebral metabolism of [2-13C]acetate and [1-13C]glucose: an ex vivo 13C
NMR spectroscopic study. J. Neurochem. 64, 2773–2782.
Hildebrandt, F., 1926. Pentamethylenetetrazol (Cardiazol). Archiv für
experimentelle Pathologie und Pharmakologie 116, 100–109.
Janigro, D., 1999. Blood-brain barrier, ion homeostatis and epilepsy: possible
implications towards the understanding of ketogenic diet mechanisms.
Epilepsy Res. 37, 223–232.
Januszewicz, E., Pajak, B., Gajkowska, B., Samluk, L., Djavadian, R.L., Hinton, B.T.,
Nalecz, K.A., 2009. Organic cation/carnitine transporter OCTN3 is present in
astrocytes and is up-regulated by peroxisome proliferators-activator receptor
agonist. Int. J. Biochem. Cell Biol. 41, 2599–2609.
Januszewicz, E., Bekisz, M., Mozrzymas, J.W., Nalecz, K.A., 2010. High afﬁnity
carnitine transporters from OCTN family in neural cells. Neurochem. Res. 35,
743–748.
Johannessen, C.U., Petersen, D., Fonnum, F., Hassel, B., 2001. The acute effect of
valproate on cerebral energy metabolism in mice. Epilepsy Res. 47, 247–256.
Karler, R., Murphy, V., Calder, L.D., Turkanis, S.A., 1989. Pentylenetetrazol kindling in
mice. Neuropharmacol 28, 775–780.
Kido, Y., Tamai, I., Ohnari, A., Sai, Y., Kagami, T., Nezu, J., Nikaido, H., Hashimoto, N.,
Asano, M., Tsuji, A., 2001. Functional relevance of carnitine transporter OCTN2
to brain distribution of L-carnitine and acetyl-L-carnitine across the blood-brain
barrier. J. Neurochem. 79, 959–969.
Kondziella, D., Bidar, A., Urfjell, B., Sletvold, O., Sonnewald, U., 2002. The
pentylenetetrazole-kindling model of epilepsy in SAMP8 mice. behavior and
metabolism. Neurochem. Int. 40, 413–418.
Kondziella, D., Hammer, J., Sletvold, O., Sonnewald, U., 2003. The
pentylenetetrazole-kindling model of epilepsy in SAMP8 mice. glial-neuronal
metabolic interactions. Neurochem. Int. 43, 629–637.
Kuratsune, H., Watanabe, Y., Yamaguti, K., Jacobsson, G., Takahashi, M., Machii, T.,
Onoe, H., Onoe, K., Matsumura, K., Valind, S., Kitani, T., Langstrom, B., 1997. High
uptake of [2-11C]acetyl-L-carnitine into the brain: a PET study. Biochem.
Biophys. Res. Com. 231, 488–493.
Lefevre, F., Aronson, N., 2000. Ketogenic diet for the treatment of refractory epilepsy
in children: a systematic review of efﬁcacy. Pediatrics 105, E46.
Lei, H., Duarte, J.M., Mlynarik, V., Python, A., Gruetter, R., 2010. Deep thiopental
anesthesia alters steady-state glucose homeostasis but not the neurochemical
proﬁle of rat cortex. J. Neurochem. Res. 88, 413–419.
Leiderman, D.B., Balish, M., Bromﬁeld, E.B., Theodore, W.H., 1991. Effect of valproate
on human cerebral glucose metabolism. Epilepsia 32, 417–422.
Loscher, W., 1981. Valproate induced changes in GABA metabolism at the
subcellular level. Biochem. Pharmacol. 30, 1364–1366.
Loscher, W., 1999. Valproate: a reappraisal of its pharmacodynamic properties and
mechanisms of action. Prog. Neurobiol. 58, 31–59.
Loscher, W., 2002. Basic pharmacology of valproate: a review after 35 years of
clinical use for the treatment of epilepsy. CNS Drugs 16, 669–694.
Loscher, W., Honack, D., Fassbender, C.P., Nolting, B., 1991. The role of technical,
biological and pharmacological factors in the laboratory evaluation of
anticonvulsant drugs III. Pentylenetetrazole seizure models. Epilepsy Res. 8,
171–189.
Maciejak, P., Szyndler, J., Turzynska, D., Sobolewska, A., Bidzinski, A., Kolosowska, K.,
Plaznik, A., 2010. Time course of changes in the concentrations of amino acids in
the brain structures of pentylenetetrazole-kindled rats. Brain Res. 1342, 150–
159.
Mason, C.R., Cooper, R.M., 1972. A permanent change in convulsive threshold in
normal and brain-damaged rats with repeated small doses of pentylenetetrazol.
Epilepsia 13, 663–674.
Meisingset, T.W., Risa, O., Brenner, M., Messing, A., Sonnewald, U., 2010. Alteration
of glial-neuronal metabolic interactions in a mouse model of Alexander disease.
Glia 58, 1228–1234.
Melo, T.M., Nehlig, A., Sonnewald, U., 2005. Metabolism is normal in astrocytes in
chronically epileptic rats: a (13)C NMR study of neuronal-glial interactions in a
model of temporal lobe epilepsy. J. Cereb. Blood Flow Metab. 25, 1254–1264.
Morimoto, K., Fahnestock, M., Racine, R.J., 2004. Kindling and status epilepticus
models of epilepsy: rewiring the brain. Prog. Neurobiol. 73, 1–60.
Norenberg, M.D., Martinez-Hernandez, A., 1979. Fine structural localization of
glutamine synthetase in astrocytes of rat brain. Brain Res. 161, 303–310.
Nutt, D.J., Taylor, S.C., Little, H.J., 1986. Optimizing the pentetrazol infusion test for
seizure threshold measurement. J. Pharm. Pharmacol. 38, 697–698.
Ohno, Y., Ishihara, S., Terada, R., Serikawa, T., Sasa, M., 2010. Antiepileptogenic and
anticonvulsive actions of levetiracetam in a pentylenetetrazole kindling model.
Epilepsy Res. 89, 360–364.
Ori, C., Freo, U., Pizzolato, G., Dam, M., 2002. Effects of acetyl-L-carnitine on regional
cerebral glucose metabolism in awake rats. Brain Res. 951, 330–335.
Parnetti, L., Gaiti, A., Mecocci, P., Cadini, D., Senin, U., 1992. Pharmacokinetics of IV
and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile
dementia of Alzheimer type. European J. Clin. Pharm. 42, 89–93.
Pati, S., Alexopoulos, A.V., 2010. Pharmacoresistant epilepsy: from pathogenesis to
current and emerging therapies. Cleve Clin. J. Med. 77, 457–467.
Petroff, O.A., Errante, L.D., Rothman, D.L., Kim, J.H., Spencer, D.D., 2002. Glutamate-
glutamine cycling in the epileptic human hippocampus. Epilepsia 43, 703–710.
Planas, A.M., Soriano, M.A., Ferrer, I., Rodriguez Farre, E., 1994. Regional expression
of inducible heat shock protein-70 mRNA in the rat brain following
administration of convulsant drugs. Brain Res. Mol. Brain Res. 27, 127–137.
Qu, H., Eloqayli, H., Sonnewald, U., 2005. Pentylenetetrazole affects metabolism of
astrocytes in culture. J. Neurosci. Res. 79, 48–54.
Ramanjaneyulu, R., Ticku, M.K., 1984. Interactions of pentamethylenetetrazole and
tetrazole analogues with the picrotoxinin site of the benzodiazepine-GABA
receptor-ionophore complex. Eur. J. Pharmacol. 98, 337–345.
Sarkisian, M.R., 2001. Overview of the Current Animal Models for Human Seizure
and Epileptic Disorders. Epilepsy Behav. 2, 201–216.
Scaﬁdi, S., Fiskum, G., Lindauer, S.L., Bamford, P., Shi, D., Hopkins, I., McKenna, M.C.,
2010. Metabolism of acetyl-L-carnitine for energy and neurotransmitter
synthesis in the immature rat brain. J. Neurochem. 114, 820–831.
Smeland, O.S., Meisingset, T.W., Sonnewald, U., 2012. Dietary supplementation with
acetyl-L-carnitine improves brain energy metabolism in healthy mice and
increases noradrenaline and serotonin content. Neurochem. Int. in press. PMID:
22709675.
Squires, R.F., Saederup, E., Crawley, J.N., Skolnick, P., Paul, S.M., 1984. Convulsant
potencies of tetrazoles are highly correlated with actions on GABA/
benzodiazepine/picrotoxin receptor complexes in brain. Life Sci. 35, 1439–
1444.
Starr, M.S., 1996. The role of dopamine in epilepsy. Synapse 22, 159–194.
Szyndler, J., Maciejak, P., Turzynska, D., Sobolewska, A., Bidzinski, A., Plaznik, A.,
2010. Time course of changes in the concentrations of monoamines in the brain
structures of pentylenetetrazole-kindled rats. J. Neural. Transm. 117, 707–718.
Valente, T., Dominguez, M.I., Bellmann, A., Journot, L., Ferrer, I., Auladell, C., 2004.
Zac1 is up-regulated in neural cells of the limbic system of mouse brain
O.B. Smeland et al. / Neurochemistry International 61 (2012) 444–454 453
following seizures that provoke strong cell activation. Neuroscience 128, 323–
336.
Willis, S., Stoll, J., Sweetman, L., Borges, K., 2010. Anticonvulsant effects of a
triheptanoin diet in two mouse chronic seizure models. Neurobiol. Dis. 40, 565–
572.
Yudkoff, M., Daikhin, Y., Nissim, I., Horyn, O., Lazarow, A., 2003. Metabolism of brain
amino acids following pentylenetetrazole treatment. Epilepsy Res. 53, 151–162.
Yudkoff, M., Daikhin, Y., Melo, T.M., Nissim, I., Sonnewald, U., 2007. The ketogenic
diet and brain metabolism of amino acids: relationship to the anticonvulsant
effect. Annu. Rev. Nutr. 27, 415–430.
454 O.B. Smeland et al. / Neurochemistry International 61 (2012) 444–454

  
 
 
Paper III
 
Is not included due to copyright 


